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Abstract 
 
Kidney disease is a worldwide public health problem associated with an increased 
cardiovascular risk and all cause mortality. End-stage renal disease is defined by 
the cessation of effective kidney function and the beginning of renal replacement 
therapy, such as hemodialysis, peritoneal dialysis or kidney transplantation. The 
renal replacement therapy of choice for end-stage renal disease is kidney 
transplantation. It is widely accepted that kidney transplantation improves quality 
and length of life, and costs less than dialysis. 
Kidney transplantation demands immunosuppressant therapy to avoid renal 
transplant rejection. The recent expansion in immunosuppressive agents licensed 
for use in renal transplant recipients has dramatically increased the number of 
potential drug combinations available to the clinician. 
In current literature, the comparison of calcineurin inhibitors effects on oral health 
is of great interest; however fewer studies are found concerning inhibitors mTOR 
(mammalian target of rapamycin) effects on oral health. 
Oral manifestations of CKD are common. In chronic dialysis patients dental 
diseases are considered less prevalent and periodontal diseases are more common. 
In renal transplant recipients drug induced complications and infections are the 
most important. In literature it is suggested that the inflammatory or infectious 
local burden associated to periodontal disease can predispose to bacteremia and it 
can lead to an increased cardiovascular disease risk. 
The aim of the present study was to evaluate the differences in the oral health 
status of renal transplant recipients (RTRs) administrated with Cyclosporin A 
(CsA), Tacrolimus (Tac) or Everolimus (ERL), and compare it with patients on 
hemodialysis (pre-transplant) and healthy controls (living kidney donor). 
Furthermore, oral microbiota, salivary and serum biochemical parameters will be 
studied when alterations in oral health status are observed among groups. 
A total of 88 RTRs have participated in the study, 29 of these were RTRs receiving 
CsA, 36 were RTRs receiving Tac and 23 were RTRs receiving ERL. Additionally, 13 
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LKDs and 23 HD patients were used as control groups. Demographic and 
pharmacological data were recorded in all groups. Oral health status was assessed 
through the analysis of oral hygiene habits and oral symptoms, teeth evaluation 
(visible plaque index and DMFT index), periodontal evaluation (bleeding on 
probing, clinical attachment level), gingival enlargement, gingival index, salivary 
pH and flow rate. 
Oral fungi colonization was assessed by isolation and quantification for all studied 
groups. Saliva composition was assessed through the quantification of its 
parameters using an automatic analyzer. The relation between salivary and serum 
biochemical parameters was studied by calculating a ratio. 
Renal transplant recipients receiving Tac were younger than CsA, ERL, HD and 
LKD-groups, whereas the prevalence of female gender was higher in LKDs group. 
No differences were found among the studied groups concerning smoking habits. 
When RTRs were compared to HD and LKD groups no differences were found 
among the three groups concerning oral hygiene habits and oral symptoms. No 
differences were observed in teeth and periodontal evaluation. Although 
unstimulated and stimulated saliva pH did not differ among groups, unstimulated 
and stimulated saliva flow rates were lower in HD patients than in RTRs and LKD 
groups. Concerning oral fungi colonization no differences were found among the 
studied groups. 
When RTRs receiving CsA, Tac or ERL were compared, no differences were found 
among the three groups concerning oral hygiene habits and oral symptoms. 
Additionally, no differences were found in teeth and periodontal evaluation, except 
for bleeding on probing which presented itself as lower in ERL than in CsA and Tac 
groups. No differences were observed in unstimulated and stimulated saliva flow 
rate and pH among the three groups. 
Saliva composition revealed differences when HD patients, RTRs and LKDs were 
compared. Patients on hemodialysis presented higher levels of potassium, urea, 
creatinine, lipid profile (LDL cholesterol, triglycerides), aspartate 
aminotransferase and alkaline phosphatase. In what concerns RTRs the main 
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results were the lower levels of immunoglobulins A and G when compared with HD 
patients and healthy controls. The saliva/serum ratio revealed itself as an 
important indicator of biochemical parameters variation, namely for potassium, 
phosphate, urea, creatinine, and lipid profile. 
Renal transplant recipients receiving ERL had less periodontal inflammation and 
may be better protected for the development of periodontal disease when 
compared to RTRs receiving Tac or CsA. 
Patients on hemodialysis had less oral cleaning than RTRs or LKDs. Concerning 
saliva composition, the lower salivary secretion rate and the potassium derived 
from serum could be responsible for the higher levels of salivary potassium 
observed; the lower salivary uric acid could lead to lower protection towards  
oxidative damage; and higher salivary levels of enzymes, namely the aspartate 
aminotransferase and alkaline phosphatase, could be associated to more tissue 
damage in oral cavity of these patients. 
Renal transplant recipients had less immunological protection in oral surfaces due 
to the lower salivary immunoglobulin A. Besides that, the higher levels of 
potassium in this group could have been determined by the salivary glands activity 
and not by serum. 
 In RTRs receiving Tac their higher salivary C-reactive protein levels could be 
considered an indicator of a higher inflammatory activity in oral tissues. In 
addition, RTRs receiving Tac and ERL could be endowed with better conditions to 
maintain dental structure, than RTRs receiving CsA. 
Saliva could be an alternative tool for monitoring the oral and systemic health and 
a sample substitute to serum in some biochemical parameters; its simplicity, 
convenience and non-invasiveness are significant advantages. 
The previous conclusions reinforce that an adequate oral health care may be 
particularly recommended for RTRs and HD patients; this is essential for their 
general health and well-being. 
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Resumo 
 
A doença renal crónica é considerada um problema de saúde pública em todo o 
mundo, e está associada a um maior risco de morbilidade e mortalidade. É 
amplamente aceite que o transplante renal melhora a qualidade e a esperança de 
vida dos indivíduos que padecem desta doença. 
No transplante renal a terapêutica imunossupressora é necessária para evitar ou 
prevenir a rejeição do órgão. Os agentes imunossupressores têm registado um 
incremento substancial no seu número o que potencia as combinações 
farmacológicas disponíveis. Na literatura recente, a comparação dos efeitos dos 
inibidores da calcineurina (ciclosporina A e tacrolimus) na saúde oral é de grande 
interesse. Contudo, poucos estudos são encontrados relativamente aos inibidores 
seletivos de mTOR - alvo da rapamicina de mamíferos (everolimus). 
As manifestações orais na doença renal crónica são comuns. Enquanto que nos 
pacientes em diálise as doenças dentárias são consideradas menos prevalentes e as 
doenças periodontais são mais comuns, nos doentes transplantados renais as 
complicações induzidas por fármacos e as infeções são as mais frequentes. Na 
literatura sugere-se que a carga inflamatória local e/ou infeciosa associada à 
doença periodontal pode predispor à bacteriemia e a um aumento do risco de 
doença cardiovascular.  
O presente estudo tem como objetivos avaliar as diferenças no estado de saúde 
oral de doentes transplantados renais medicados com Ciclosporina A (CsA), 
Tacrolimus (Tac) e Everolimus (ERL), como imunossupressores, e compará-los 
com doentes em hemodiálise (pré-transplante) e dadores vivos de rim (controlos 
saudáveis). Para além disso, sempre que forem observadas alterações no estado de 
saúde oral entre os grupos estudados, a microbiota oral e os parâmetros 
bioquímicos na saliva e no sangue serão avaliados. 
No estudo participaram 88 transplantados renais, sendo 29 medicados com CsA, 
36 com Tac e 23 com ERL. Adicionalmente, 23 doentes em hemodiálise e 13 
dadores vivos de rim participaram como grupos controlo. Para todos foram 
registadas variáveis demográficas e farmacológicas. O estado de saúde oral foi 
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avaliado através da análise dos hábitos de higiene oral e sintomas orais, do exame 
dentário (índice de placa e no índice CPO) e periodontal (hemorragia pós-
sondagem, nível clínico de inserção), do aumento gengival e índice gengival, da 
análise da taxa de fluxo e do pH salivar. 
A presença de fungos na cavidade oral e a sua quantificação foram determinados 
para cada um dos grupos. A composição da saliva foi avaliada pela quantificação 
dos seus parâmetros usando um analisador automático. A relação dos parâmetros 
bioquímicos na saliva e no sangue foi avaliada através da determinação de um 
quociente. 
Os transplantados renais medicados com Tac eram mais jovens que os 
transplantados medicados com CsA ou ERL, e do que os doentes em hemodiálise e 
controlos saudáveis. A prevalência de mulheres era maior nos dadores vivos de 
rim, enquanto que a prevalência de homens era maior nos transplantados renais. 
Não foram encontradas diferenças estatisticamente significativas no que respeita 
aos hábitos tabágicos entre os grupos. Quando os transplantados renais foram 
comparados com os doentes em hemodiálise e com controlos saudáveis não foram 
observadas diferenças nos hábitos de higiene oral e sintomas orais, e também não 
foram observadas diferenças na avaliação dentária e periodontal. Embora não 
tenham sido observadas diferenças no pH da saliva, a taxa de fluxo da saliva não 
estimulada e estimulada foi menor nos doentes em hemodiálise do que nos 
transplantados renais e controlos saudáveis. No que diz respeito à presença de 
fungos na cavidade oral não foram observadas diferenças nos grupos estudados. 
A comparação entre os transplantados renais medicados com CsA, Tac e ERL não 
revelou diferenças no que respeita aos hábitos de higiene oral e sintomas orais. O 
mesmo se verificou na avaliação dentária e periodontal, com exceção do índice de 
hemorragia pós-sondagem que se apresentou menor no grupo de transplantados 
renais medicados com ERL do que nos grupos medicados com CsA e Tac. Não 
foram observadas diferenças no pH e taxa de fluxo salivar entre os três grupos de 
transplantados. 
A composição da saliva revelou diferenças quando foram comparados os doentes 
em hemodiálise com os transplantados renais e controlos saudáveis. Os doentes 
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em hemodiálise apresentaram níveis mais elevados de potássio, ureia, creatinina, 
perfil lipídico (colesterol LDL e triglicerídeos), e enzimas, aspartato 
aminotransferase e fosfatase alcalina. Os transplantados renais apresentaram 
níveis mais baixos de imunoglobulinas A e G quando comparados com os doentes 
em hemodiálise e controlos saudáveis. O quociente dos parâmetros bioquímicos na 
saliva e no sangue revelou-se como um importante indicador para o potássio, 
fosfato, creatinina, ureia e perfil lipídico. 
Os doentes transplantados renais medicados com ERL têm menos inflamação 
periodontal e parecem estar melhor protegidos para a doença periodontal, quando 
comparados com os transplantados renais medicados com CsA e Tac. 
Nos doentes em hemodiálise a capacidade de remoção das bactérias e resíduos 
pela secreção de saliva foi menor. Relativamente à composição da saliva, a menor 
taxa de secreção salivar e o potássio derivado do sangue poderão estar na origem 
dos níveis elevados de potássio observados; os níveis mais baixos de ácido úrico 
podem condicionar uma menor proteção antioxidante; e níveis mais altos das 
enzimas, aspartato aminotransferase e fosfatase alcalina, podem ser indicadores 
de maiores danos nos tecidos orais destes doentes, quando comparados com os 
doentes transplantados renais e os controlos saudáveis. 
Os doentes transplantados renais apresentaram uma menor proteção imunológica 
nas mucosas orais devido aos baixos níveis salivares de imunoglobina A. Os níveis 
elevados de potássio na saliva para este grupo podem ter sido determinados pela 
atividade das glândulas salivares e não pela influência do sangue. Uma maior 
atividade inflamatória nos tecidos orais pode existir nos doentes transplantados 
renais medicados com Tac, considerando os elevados níveis de proteína C reativa 
detetados na saliva deste grupo. Considerando também os elevados níveis de 
fosfato encontrados na saliva dos doentes transplantados renais medicados com 
Tac e ERL, estes podem estar dotados de melhores condições para proteger a sua 
estrutura dentária do que os transplantados medicados com CsA. 
A saliva pode ser uma ferramenta útil para monitorizar a saúde oral e sistémica, e 
também uma amostra alternativa ao sangue para mensuração de alguns 
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parâmetros bioquímicos. A simplicidade da sua colheita, a sua conveniência para o 
paciente e o facto de não ser invasiva, são vantagens deveras importantes. 
As conclusões anteriores vêm reforçar que os cuidados médicos dentários nos 
doentes transplantados renais e doentes em hemodiálise são particularmente 
recomendados, sendo mesmo indispensáveis para o seu estado de saúde geral e 
bem-estar. 
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Chapter I – Introduction 
 
 
 
1 Chronic kidney disease 
Kidney disease is a worldwide public health problem recognized as a common 
condition that is associated with an increased risk of cardiovascular disease and 
chronic renal failure, with poor outcomes and high cost. [1] 
Kidneys are two structurally complex organs that evolved to regulate several 
important functions such as: fluid volume and maintenance of acid/base balance of 
plasma, excretion the waste products of metabolism such as nitrogenous waste, 
regulation of body water and salt, secretion of a variety of hormones and autacoids 
and drug metabolism. [1-3] 
Under normal physiological conditions, 25% of the circulating blood perfuses the 
kidney each minute. The blood is filtered through a complex network of tubules 
and glomerular capillaries, resulting in the ultrafiltrate, the precursor of urine. [3, 4] 
Progressive kidney disease can result in reduced function and might affect several 
organ systems. Resultant anemia, abnormal bleeding, electrolyte and fluid 
imbalance, hypertension, drug intolerance, and skeletal abnormalities might affect 
the practice of dentistry. [1, 2] 
Additionally, patients who have severe progressive disease may require artificial 
filtration of the blood through dialysis or kidney transplantation. These patients 
have become important in dentistry because of the growing number that survives 
renal failure due to renal dialysis or transplantation. [1, 2] 
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The Kidney Disease Outcomes Quality Initiative (K/DOQI) of the National Kidney 
Foundation (NKF) defines chronic kidney disease (CKD) as either kidney damage 
or a decreased glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m2 for 
3 or more months [5]. Whatever the underlying etiology, the destruction of renal 
mass with irreversible sclerosis and loss of nephrons leads to a progressive decline 
in GFR. The different stages of CKD form a continuum in time. In 2002, K/DOQI 
published its classification of the stages of CKD, as follows: stage 1, kidney damage 
with normal or increased GFR (>90 mL/min/1.73 m2); stage 2, mild reduction in 
GFR (60-89 mL/min/1.73 m2); stage 3, moderate reduction in GFR (30-59 
mL/min/1.73 m2); stage 4, severe reduction in GFR (15-29 mL/min/1.73 m2); and 
stage 5, kidney failure (GFR < 15 mL/min/1.73 m2 or dialysis). [4, 5] 
The stage of CKD provides substantial prognostic and diagnostic information about 
outcomes, progression to end-stage renal disease (ESRD) and mortality [6, 7]; 
occurrence of intercurrent morbidity, ischemic heart disease, stroke and 
peripheral vascular disease [8, 9]; and it is predictive of complications prevalence 
associated with impaired kidney function, anemia, bone disease, and nutritional 
and functional status. [4] 
Chronic kidney disease is associated to several complications, such as alteration of 
GFR [5]; proteinuria [10]; decreased quality of life, namely, difficulty on walking [5] 
and hemoglobin variation [11]; and outcomes, 5-year end stage renal disease rate, 5-
year mortality rate, 3-year cardiovascular disease rate [6]. It is also related to risk 
factors, like cardiovascular, as hypertension [5], diabetes [10] and C-reactive protein 
[12]; nutritional, as albumin [12] and bicarbonate [12]; and bone disease, as phosphate 
[5, 13], calcium [5, 13], 25(OH)-vitamin D [13] and parathormone. [4, 13] 
1.1 End-stage renal disease 
End-stage renal disease is defined by the cessation of effective kidney function and 
the beginning of renal replacement therapy (RRT), such as hemodialysis (HD), 
peritoneal dialysis or kidney transplantation. The cessation of effective kidney 
function refers to bilateral, progressive, chronic deterioration of nephrons, the 
functional unit of the kidney. [3, 4, 14] 
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In the last 3 decades, an epidemic of ESRD, initially attributed to the dissemination 
and adoption of RRT, has occurred in both industrialized and developing countries 
[15, 16] and has been responsible for an increase in life expectancy. Epidemic ESRD 
has a substantial impact in public health. [4] 
Patients treated for ESRD, when compared with individuals matching age-, gender- 
and ethnicity, have a shorter life expectancy. Furthermore, treatment is punctuated 
by frequent hospitalizations, progressive disability and worse quality of life. [4, 17, 18] 
1.2 Epidemiology 
1.2.1 Incidence and prevalence in Portugal 
In Portugal there are 900 000 patients with kidney disease, and 1 in each 10 
individuals suffers from CKD. Every year, are recorded 2 500 new cases of ESRD 
and there are at this time 16 000 patients with the most severe form of CKD, 
undergoing dialysis (about 10 000) or kidney transplant (6 000). [19] 
1.2.2 Etiology 
ESRD is caused by any condition that destroys nephrons. The three most common 
causes of ESRD are diabetes mellitus (34%), hypertension (25%), and chronic 
glomerulonephritis (16%). Other common causes include polycystic kidney 
disease, systemic lupus erythematosus, neoplasm, and acquired immunodeficiency 
syndrome (AIDS) nephropathy. Hereditary and environmental factors such as 
amyloidosis, congenital disease, hyperlipidemia, immunoglobulin A nephropathy, 
and silica exposure also contribute to the disease. [3] 
1.2.3 Pathophysiology and complications 
Human kidneys are two bean-shaped organs, one on each side of the spinal cord, 
and each one of them contains from one to two million nephrons. They represent 
about 0.5% of the total weight of the body and remarkably receive 20–25% of the 
total arterial blood pumped by the heart. [1] 
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Deterioration and destruction of functioning nephrons are the underlying 
pathologic processes of ESRD. The nephron includes the glomerulus, tubules and 
vasculature. Various diseases may affect different segments of the nephron at first, 
but the entire nephron can be eventually affected. Once lost, nephrons are not 
replaced. [3] 
Nephron deterioration leads to successive laboratory and clinical stages. The first 
stage, called diminished renal reserve, is usually asymptomatic and is 
characterized by a mildly elevated creatinine level and a slight decline in GFR 
(10% to 20% change from normal). Progression leads to renal insufficiency, a term 
that is used when the GFR is mildly to moderately diminished, 20% to 50% of 
normal, and nitrogen products begin to accumulate in blood. In the third stage, 
called renal failure, the ability of the kidney to perform excretory, endocrine, and 
metabolic functions has deteriorated beyond compensatory mechanisms. This 
indicates that kidneys are unable to maintain normal homeostasis. The resultant 
clinical syndrome - caused by renal failure, retention of excretory products, and 
interference with endocrine and metabolic functions – is called uremia. Sequelae 
involve multiorgan systems including cardiovascular, hematologic, neuromuscular, 
endocrine, gastrointestinal, and dermatologic manifestations. [3, 4] 
Among the most important complications of ESRD are the development of fluid 
overload, hypertension and risk of cardiac disease, which is caused by kidney 
incapacity to concentrate and filtrate the intake of sodium. Arterial hypertension is 
the most common; NaCl retention, fluid overload and inappropriately high rennin 
levels cause it. The cardiovascular system is affected by a tendency to develop 
congestive heart failure or pulmonary edema, or even both. [3] 
There are also other complications as:  azotemia, acidosis, electrolyte disturbances, 
anemia, hemorrhagic diatheses, committed host defense, renal osteodystrophy, 
and secondary hyperparathyroidism. [3] 
Azotemia refers to the buildup of nonprotein nitrogen compounds, mainly urea, in 
the blood. [3] 
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Acidosis results from the combination of waste products, mostly ammonia 
retention. Patients with acidosis suffer of nausea, anorexia and fatigue, and due to 
adaptive mechanisms they tend to hyperventilate, which eventually may be fatal.[3] 
Electrolyte disturbances, sodium depletion and hyperkalemia, occur as azotemia 
progresses, urine output falls and acid/base balance continues to deteriorate. [3] 
Anemia is caused by decreased erythropoietin production by the kidney, inhibition 
of red blood cell production and hemolysis, bleeding episodes, and shortened red 
cell survival. [3] 
Hemorrhagic diatheses, spontaneous or near spontaneous bleeding caused by a 
defect in clotting mechanisms (blood coagulation disorders) or another 
abnormality causing a structural flaw in the blood vessels (vascular hemostatic 
disorders), are common in patients with ESRD and are mainly attributed to 
abnormal platelet aggregation and adhesiveness, decreased platelet factor 3, 
impaired prothrombin consumption and defective platelet production. [3] 
Host defense is compromised by nutritional deficiencies and changes in the 
production and function of white blood cells, therefore patients with these 
conditions are more susceptible to infection. [3] 
Renal osteodystrophy includes a variety of bone disorders. The progression of 
osseous changes begins with osteomalacia (increased unmineralized bone matrix), 
it is followed by osteitis fibrosa (bone resorption, lytic lesions and marrow 
fibrosis), and finally, osteosclerosis in varying degrees (enhanced bone density). [3] 
1.3 Clinical presentation 
Clinical presentation of ESRD may be variable according to the severity of the 
disease and the context of the patient’s overall physical status. [3] 
1.3.1 Signs and symptoms 
Patients with ESRD might be affected by conditions that will manifest as common 
signs and symptoms as anemia, hyperpigmentation, “uremic frost”, multiorgan 
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system involvement, uremic syndrome, stomatitis, bleeding diatheses and 
cardiovascular related events. [3] 
Patients generally appear ill and anemic and may develop nocturia. Anemia 
produces pallor of the skin and mucous membranes and contributes to the 
symptoms of lethargy, listlessness and dizziness. [3] 
Hyperpigmentation of the skin is characterized by a brownish-yellow appearance 
caused by the kidney, pigments and might cause profound pruritus. [3] 
“Uremic frost” is an occasional finding, refers to a whitish coating on the skin of the 
trunk and arms produced by residual urea crystals left when perspiration 
evaporates. [3] 
Some of the organs involved are those from gastrointestinal system that provides 
signs such as anorexia, nausea, and vomiting, generalized gastroenteritis, and 
peptic ulcer disease. Cardiovascular system is also involved and presents signs 
such as shortness of breath, orthopnea and dyspnea on exertion, and peripheral 
edema. [3] 
Uremic syndrome usually causes malnutrition and diarrhea, patients show mental 
slowness or depression and become psychotic in later stages, muscular 
hyperactivity, convulsion, which is a late finding and it could be directly correlated 
with the level of azotemia, stomatitis, manifested by oral ulceration and eventually 
candidiasis, parotitis and breath odor like urine. [3] 
In what concerns bleeding diatheses, they can manifest as hemorrhagic episodes, 
particularly occult gastrointestinal bleeding, and it can also manifest as 
ecchymosis, petechiae, purpura, gingival or mucous membrane bleeding, and 
epistaxis. [3] 
1.3.2 Laboratory findings 
To monitor the progress of ESRD several tests are used such as: urinalysis, Blood 
Urea Nitrogen (BUN) Test, serum creatinine, creatinine clearance, electrolyte 
measurements, and protein electrophoresis. [3] 
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The most basic test of kidney function is urinalysis, with special emphasis on 
specific gravity and the presence of protein. [3] 
Among the referred tests, three are used primarily to assess renal function: 
creatinine clearance, serum creatinine and GFR. Creatinine is a measure of muscle 
breakdown and filtration capacity of the nephron. It is proportionate to the 
glomerular filtration and tubular excretion rates and commonly is used as the 
index of clearance (creatinine clearance) in a 24-hour urine collection. [3] 
The BUN is a common indicator of kidney function but is not as specific as 
creatinine level. [3] 
1.4 Oral manifestations 
The widespread of ESRD effects also implicate the involvement of stomatognatic 
apparatus, which can suffer a variety of oral signs: mucosal pallor (anemia), 
xerostomia, purpura, mucosal ulceration, white epithelial plaques, enamel 
hypoplasia and giant-cell lesions of the jaws. [3, 20] 
1.4.1 Mucosal pallor 
The pallor of the oral mucosa is related to anemia, which is one of most common 
oral changes affecting patients with ESRD.  Another colour alteration is red-orange 
discoloration of the cheeks and mucosa, caused by pruritus and deposition of 
carotene-like pigments that occurs when renal filtration is decreased. [3] 
1.4.2 Xerostomia 
Xerostomia refers to a subjective sensation of dry mouth that may be associated or 
not with an impaired salivary function.  A number of factors may play a role in the 
cause of xerostomia such as: developmental alterations, water or metabolite loss, 
iatrogenic origin, systemic diseases and local factors. [20-24] Additionally, a large 
number of commonly used medications, including drugs against psychiatric 
disorders and hypertension, have side effects of dry mouth, decreased saliva flow 
rate, and/or altered saliva composition. [21-23, 25] 
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The patient´s symptoms not always correspond to the clinical findings, in fact, 
some patients who complain of dry mouth may appear to have adequate salivary 
flow and oral moistness and conversely, some patients who clinically appear to 
have a dry mouth have no complaints. [20, 26] 
In patients with reduced saliva flow rates all protective functions of saliva are 
negatively affected. [21] As a result, patients will have an increased caries 
experience, increased prevalence of oral candidiasis, due to reduction in the 
cleansing and antimicrobial activity normally provided by saliva, and patients may 
complain of difficulty with mastication and swallowing. [20, 21, 27-34] 
Because of the increased potential for dental caries in patients with xerostomia, 
frequent dental visits are recommended. Office and daily home fluoride 
applications can be used to help prevent decay, and chlorhexidine mouth rinses 
minimize plaque buildup. [20] 
1.4.3 Purpura 
Purpura is a submucosal hemorrhage (Figure 1), which size is less than 2 cm. 
Purpura can arise from repeated or prolonged increased intrathoracic pressure 
and traumatic or non traumatic hemorrhage. When hemorrhage results from non 
traumatic causes, clinician should consider anticoagulant therapy, 
thrombocytopenia, disseminated intravascular coagulation (DIC) and a number of 
viral infections, especially infectious mononucleosis and measles, as possible 
causes. [20] 
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Figure 1. Submucosal hemorrhage. 
 
1.4.4 Mucosal ulceration 
Ulceration in the mouth is an open sore and it refers to a discontinuity of the oral 
mucosa that unable its normal functions. [20] 
Ulceration may be an early manifestation, predating urinary abnormalities or renal 
failure. It is well recognized that new ulceration predicts increasing disease 
activity. Interestingly, there appears to be a link between oral ulceration and the 
development of lupus nephritis in patients with systemic lupus erythematosus, 
which could reflect an increased immunological organ injury. [35-37] 
Mucosal ulceration might be an adverse effect of immunossupressive agents, such 
as mycophenolate mofetil, because it may cause inflammation and ulceration 
throughout the gut and it may give rise to painful oral ulceration, particularly in 
combination with sirolimus. [38] Henoch-Schonlein purpura can rarely present oral 
ulceration. [35] 
 
STUDY OF ORAL HEALTH STATUS IN RENAL TRANSPLANT RECIPIENTS 
Introduction 
 
 
10 
1.4.5 White epithelial plaques 
The presence of white epithelial plaques on the oral mucosa (Figure 2) might be 
caused by uremic stomatitis, a rare oral mucosal disorder associated with chronic 
renal failure, and it appears as adherent white plaques on any part of the oral 
mucosa, and may look like more common lesions such as lichen planus, chronic 
hyperplastic candidiasis, or even hairy leukoplakia. [35] 
The cause of these often painful lesions is not known, but it is suggested the 
conversion of salivary urea by bacterial ureases to ammonia that causes a 
‘chemical burn’. [35, 39] 
Uremic stomatitis in severe renal failure is early presented as red, burning mucosa 
covered with gray exudates and later as ulceration. [39] 
Another white epithelial plaque is called “uremic frost” that is caused by urea 
crystal deposition. It is more common on the skin but may be seen on the oral 
mucosa too. [40] 
 
Figure 2. White epithelial plaque. 
 
1.4.6 Enamel hypoplasia
Enamel hypoplasia is a defect in the teeth
hard but thin and it is deficient in amount. This is caused by defective enamel 
matrix formation with a deficiency in the cementing substance. 
Enamel hypoplasia has been documented in patients with ESRD whose disease 
began at an early age. In the developing dentition, it also have been reported red
brown discoloration and delayed or altered erupti
complication due patient persistent vomiting. Caries, however, is not a feature 
because salivary urea inhibits the metabolic end products of bacterial plaque and 
increases the buffering capacity of saliva, thus preventing a dro
attain cariogenic levels. [3]
 
1.4.7 Giant-cell lesions of the jaws
Giant-cell lesions of the jaws are lytic bone lesions caused by secondary 
hyperparathyroidism. Other osseous findings include widened trabeculations, loss 
of cortication, calcification, calcified extraction sites (“socket sclerosis”), and 
metastatic calcifications within the skull. ESRD contribute to the development of 
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specific osseous changes of the jaws. The most classically described osseous 
change is the triad of loss of lamina dura, demineralized bone (“ground glass”), and 
localized radiolucent jaw lesions (central giant cell granulomas; “brown tumor”). [3] 
 
2 Medical management of chronic kidney disease 
On ESRD patients the following medical management can be used: conservative 
care, dialysis and kidney transplantation. 
2.1 Conservative Care 
Once the diagnosis of ESRD has been made, the goals of the treatment are to retard 
the progress of disease and to preserve the patient’s quality of life. A conservative 
approach is the first step and may be adequate for prolonged periods. [3, 4] 
Conservative care aims to slow the progression of kidney disease, avoiding 
nephrotoxic drugs or agents metabolized principally by it. To accomplish that is 
necessary to decrease the retention, fluids and electrolyte imbalances. This is 
possible by dietary modification-restricting protein and monitoring fluid, sodium, 
and potassium intake. Any treatable associated condition such as diabetes, 
hypertension, congestive heart failure, infection, volume depletion, urinary tract 
obstruction, secondary hyperparathyroidism, and hyperuricemia is corrected or 
controlled. In particular, secondary hyperparathyroidism is treated with low-
phosphate binders (e.g., calcium carbonate), calcitriol, and other vitamin D 
preparations that decrease serum parathyroid hormone levels. Anemia is treated 
with use of recombinant human erythropoietin. [3] 
2.2 Dialysis 
Dialysis is a therapy able to extend life, it refers to a medical procedure that 
artificially filters the blood and it becomes necessary when the number of 
nephrons diminishes to the point that azotemia is unpreventable or 
uncontrollable. The procedure can be accomplished by peritoneal dialysis or by 
HD. [3, 4] 
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According to the Dialysis Outcomes and Practice Patterns Study (DOPPS) the 
mortality risk is relatively high in the early phase after initiation of dialysis, and 
among the causes of death there are those related to atherosclerotic heart disease 
and congestive heart failure. Additionally, the infection associated with catheter 
use for vascular access is also a cause of death. [4] 
Most dialysis patients, 90%, receive HD. This treatment is performed every 2 or 3 
days, depending on need, and it is usually required 3 to 4 hours for each session. 
Therefore HD consumes an enormous amount of the patient´s time what interferes 
with their daily routine. Between dialysis session, patients have a relatively normal 
life. [3] 
Most patients receive HD through a permanent and surgically placed 
arteriovenous graft or fistula, usually placed in the forearm. Patients are “plugged 
in” to the HD machine at the fistula/graft site, and blood is passed through the 
machine, filtered, and returned to the patient. Heparin is usually administered 
during the procedure to prevent clotting. This procedure and the fact that HD only 
provides about 15% of normal renal function are both responsible for the 
development of complications such as: anemia, muscle tetany, over secretion of 
parathyroid hormone, risk of hepatitis B, C, and human immunodeficiency virus 
(HIV) infections, platelet destruction by mechanical trauma, development of 
osteomalacia. Other complication is the infection of the arteriovenous fistula that 
can result in septicemia, septic emboli, infective endarteritis and infective 
endocarditis. The risk of fistula infection from surgical procedures in dentistry is 
not precisely known but is considered low. [3] 
Dental and oral status of patients receiving hemodialysis therapy 
Patients receiving HD are at risk to oral complications and alterations in salivary 
composition and output. Additionally, vomiting and reduced oral (self) care could 
also negatively affect the oral health resulting in more caries, higher plaque and 
calculus indices, periodontitis and oral lesions. Symptoms like uremic odor, dry 
mouth, taste change, and tongue and mucosal pain are more frequent in these 
patients than among healthy patients. Similarly, some studies showed higher rates 
of oral pathology such as xerostomia, narrowing of the pulp chamber, enamel 
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abnormalities, and premature bone loss when compared with the general 
population (Figure 4). [3, 14, 35, 41] 
HD patients are described in literature as having poor dental hygiene and the 
dental calculus may form faster, because of an imbalance in the calcium phosphate 
in serum [14, 35]. Moreover, plaque-related diseases can prove to be a source of 
active infection in these patients so it is recommended active oral treatment. [14, 41] 
 
Figure 4. Premature bone loss and poor dental hygiene. 
 
A taste disturbance is another complication of HD and might be caused by 
metabolic disturbances, the use of medication, a diminished number of taste buds 
and changes in salivary flow rate. [2] 
Patients on hemodialysis might complain of an enlargement of the tongue and a 
metallic taste before each dialysis session, which are related to anemia and uremia. 
[14] 
Literature reveals conflicting data about the effect of HD on oral health status. If for 
one hand it has been suggested that the caries activity is lower, calculus formation 
is enhanced and occur alterations in the periodontal tissues, on the other, no 
differences are found in parameters such as: gingival and plaque indices, level of 
periodontal attachment or caries when compared with the general population. [2, 
14] 
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Some studies have demonstrated that periodontal health is poor in HD patients 
and it is correlated with markers of malnutrition and inflammation. One of the 
inflammatory markers described is C-reactive protein. Further than, it has been 
suggested that successful treatment of periodontitis leads to a decrease in 
inflammatory markers, with reduced C-reactive protein levels, interleukin-6, and 
tumor necrosis factor-alpha and partial restoration of endothelial dysfunction, and 
might reduce the high burden of cardiovascular disease in HD patients. [35] 
There is considerable evidence that periodontitis-related microorganisms impair 
blood rheological parameters and thereby contribute significantly to accelerated 
systemic or local diseases that cause premature death in dialyzed patients. [42] 
Xerostomia, or dry mouth, is a frequent and important complaint among HD 
patients, together with thirst it is correlated with interdialytic weight gains, which 
is a risk factor for cardiovascular morbidity. Patients that complain of dry mouth 
need regular dental review, because are predisposed to sialadenitis, caries, oral 
inflammation and infection. But there are other complaints, namely, taste 
alterations as bad taste, altered taste sensation or a metallic taste; and bad breath 
odor, experienced as ammonia-like odor. All of them are related to dry mouth and 
uremia itself. [35] 
HD patients could have secondary hyperparathyroidism (HPT), and this could lead 
to oral complications such as: craniofacial bone alterations, loss of the lamina dura 
and pulp obliteration. Secondarily to HPT, although increasingly rare, could be 
advanced renal osteodystrophy that could involve the mandible with Brown 
tumors, enlargement of the skeletal bases, increased tooth mobility, and it is 
suggested that might be related to temporomandibular complaints. [2, 14, 35] 
Premature bone loss in the jaw of HD patients also is well recognized, leading to 
mandibular and maxillary fractures. [35] 
Long-term HD patients are susceptible to amyloidosis deposition, caused by 2-
microglobulin. The tongue is a common site for it, particularly AA subtype, 
presenting as macroglossia, which may offer an accessible tissue for histological 
confirmation of the diagnosis. [20, 35] 
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Another important issue in dentistry is the dental management of HD patients that 
could be affected by important aspects related to the health status of these 
patients, namely: heparinisation before dialysis, possible hepatitis B or C carriage 
after chronic dialysis, permanent venous fistulae susceptible to infection, 
secondary hyperparathyroidism, oral lesions due to drugs and oral disease in 
chronic renal failure. [3, 20] 
Before performing an oral surgery it should be assessed the hemostasis status of 
HD patients, because HD tends to aggravate bleeding tendencies through physical 
destruction of platelets and the use of heparin. It could be done ordering a battery 
of screening tests, including PFA-100 (laboratory analyzer termed platelet function 
assay), activated partial thromboplastin time (aPTT), and platelet count. Patients 
at higher risk are those with elevated laboratory values and history of 
gastrointestinal bleeding. [3] 
To control the increased risk for bleeding in these patients, the dentist may use 
several means such as: provide dental treatment at the optimum time, usually on 
the day after HD because this treatment usually leaves the patients fatigued and 
with tendency to bleed; delay treatment until heparin is eliminated from the 
bloodstream (heparin lasts 3 to 6 hours after infusion); promote primary closure 
healing and when needed use pressure and hemostatic agents like thrombin, 
oxidized cellulose, desmopressin and tranexamic acid; performing major surgical 
procedures on the day after the end of the week of the HD treatment to provide 
additional time for clot retention before dialysis is resumed (for example, on a 
Monday/ Wednesday/ Friday weekly HD regimen, surgery performed on Saturday 
allows an additional day for clot stabilization before HD is resumed on Monday of 
the following week). The dentist may contact the nephrologist when necessary and 
request the elimination of the heparin dose during the first HD session after the 
surgical procedure (HD can be performed without heparin when hemostasis and 
clot retention are important); the dentist may also request the administration of 
protamine sulfate (usually done by a physician) if immediate care is needed 
because it will block the anticoagulant effects of heparin. [3] 
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The dentist should take into account that medication of HD patients, namely, anti-
coagulant therapy, might influence the level of inflammation (gingivitis or 
periodontitis) and induce an increased bleeding on probing. Despite the fact that 
an improvement in oral hygiene measures reduces the amount of dental plaque 
and calculus, in these cases it might not result in a bleeding reduction. [2] 
Furthermore, the dentist may consider antibiotic cover for dental surgical 
procedures, taking into account that HD patients´ permanent venous fistula for the 
dialysis lines is susceptible to infection; additionally drugs, including sedation, 
should not be given intravenously, because of the risk of damage to superficial 
veins which are patient´s lifelines. He also should be aware that HD removes some 
drugs from the circulating blood and this may shorten the duration of the effect of 
prescribed medications. Drugs removed during HD are those with low binding 
capacity to plasma proteins, on the contrary, drugs with high lipid affinity have 
high tissue binding and are not available for dialysis removal. Lastly, dosage 
amounts and intervals should be adjusted in accordance with advice from the 
patient’s physician. [3, 20] 
2.3 Kidney transplantation 
Miller initiated kidney transplantation in 1965. Nowadays it is considered a 
routine therapy for the treatment of irreversible renal failures and an alternative 
to long-term dialysis. [3, 43, 44] Interestingly, less than half of patients on dialysis are 
considered for transplantation. [4] 
It is widely accepted that kidney transplantation improves quality and length of 
life, and costs less than dialysis. However, patients have a higher risk of 
complications ranging from infection to rejection episodes and cancer, amongst 
others. [4, 45] 
Patient’s selection for kidney transplantation is an essential process but in the 
literature it is considered a problematic issue, one of the reasons is that available 
guidelines focus on patient evaluation and leave the selection to center´s 
discretion. [4] 
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Transplantation involves the surgical removal of a kidney from a donor and 
implantation of the kidney into a recipient. The donor may be a living first-degree 
relative or someone who has recently died (cadaver donor). [46] 
The treatment of choice for ESRD is the transplantation with a living donor. 
Medical evaluation of the donor is aimed to detect medical abnormalities that 
would put them at risk for donor surgery or even to develop ESRD. [47, 48] The 
evaluation also should exclude diseases like infection or malignancy that may be 
transmitted to the recipient. Living donors should represent the healthiest 
members of society. [4] 
2.3.1 Predictions of transplant outcomes 
Traditionally, the predictors of outcomes considered on kidney transplantation 
were graft and patient survival, but nowadays two key outcomes are considered, 
namely, improved survival and quality of life when compared to dialysis. [4] 
In recent years short-term patient and graft survival rates have improved 
significantly, however, no comparable improvement in long-term survival rates 
has occurred. This could be due to nephrotoxicity of some immunosuppressive 
agents like calcineurin inhibitors (CNIs), which contributes to chronic graft 
dysfunction; opportunistic infections, like emergent infections such as BK virus 
infections and infections generally assumed to have been relegated to the past 
such as cytomegalovirus (CMV) and urinary tract infections (UTI); and 
cardiovascular disease, more common than in the general population and it still is 
the leading cause of death with graft function. As a consequence, the K/DOQI 
workgroup on CKD, concluded that renal transplant recipients (RTR) should be 
considered to be in the highest risk group for cardiovascular events. [4, 45, 49, 50] 
An important aspect, related to oral health, is that low-grade untreated dental 
infection in immunocompromised individuals has been suggested to contribute for 
morbidity and even predispose to transplant rejection. [35] 
2.3.2 Chronic allograft nephropathy 
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Chronic allograft nephropathy (CAN) is a progressive renal dysfunction of the 
allograft that ultimately could lead to its loss. In literature CAN is considered a 
confusing term that lacks a proper definition. Traditionally, has been defined as a 
combination of histological features and transplant glomerulopathy. [51] Recently, 
CAN is considered a clinical diagnosis, which components are progressive 
deterioration in graft function, premature graft failure, and proteinuria, associated 
with histological changes of interstitial fibrosis, tubular loss and atrophy, and 
vascular and glomerular changes. It has two main causes: immunological, 
specifically the occurrence and severity of rejection episodes; and non-
immunological, specifically hypertension, proteinuria, hyperlipidemia, and the 
nephrotoxic effects of immunosuppressive drugs. [4, 51] 
Based up on circumstantial evidence, it is suggested that mediators of CAN are 
hyperfiltration, proteinuria, hypertension, cigarette smoking, hyperlipidemia, and 
reactive oxidative species (ROS) production. In fact, all of them are biologically 
plausible and have been reported individually to be related to future deterioration 
of transplant function and eventually graft loss. [4] 
Graft loss has major human and economic sequelae, and it is associated with major 
increments in cardiovascular and all-cause mortality risks, reflecting the reverse of 
the published survival benefits of transplantation over dialysis, and ultimately can 
lead to death. Interestingly, CAN together with primary kidney disease, represent 
50% of overall death for graft loss. [4, 52, 53] 
Despite our improved understanding on mechanisms and natural history of CAN, 
none therapeutic or prevention strategies have been established. Therefore, the 
primary aim is to minimize exposure to risk factors for development of CAN and, 
when established, is to minimize exposure to risk factors for progression, including 
modification of immunosuppressive treatment. Lately, the focus has been on the 
differential effects of immunosuppressive agents with regard to nephrotoxicity, 
specifically, the reduction or withdrawal of CNI and their replacement with non-
nephrotoxic agents, to limit the risk of allograft rejection. Nevertheless, there is 
reluctance to change immunosuppression in patients with stable graft function, 
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consequently, there are few data that supports the changing for prevent CAN, and 
the existing data demonstrates marginal benefits. [4] 
2.3.3 Immunosuppressive agents 
The commonly used immunosuppressants are the following: calcineurin inhibitors, 
namely, cyclosprorin (Sandimmun®) and tacrolimus (Prograf®); prednisone 
(Meticorten®); mycophenolate (Cellcept®); rapamycin inhibitors, such as, 
sirolimus (Rapamune®) and Everolimus (Certican®). [54-56] 
2.3.3.1 Calcineurin inhibitors 
Calcineurin inhibitors (CNIs), namely cyclosporine A (CsA) and tacrolimus (Tac), 
are immunossupressive agents that have been used since the early 1980s as a 
standard approach to reduce the number of allograft acute rejection episodes and 
enhance its short-term survival. [52] 
Recently, has been reported that the greater benefit of CNIs appears to be a 
decrease in the number of acute rejections during the first months after 
transplantation, because in the long term chronic nephrotoxicity arises as a major 
toxic effect of CNIs and is associated with mild-to-moderate renal dysfunction. [53] 
So, the balance between preventing immunological allograft failures, avoiding over 
immunosuppression and managing nephrotoxicity is still an unresolved issue. [52, 
53] 
There has been a growing interest in the possibility of eliminating or reducing 
exposure to CNIs, however some documented experiences suggests that attempts 
to withdraw CNIs must be approached with caution and assessed in various types 
of patients. [57] 
2.3.3.1.1 Cyclosporin A 
Cyclosporin (Sandimmune, Neoral, Gengraf) also termed with synonyms as CsA 
or Cyclosporin A, is used on prophylaxis of organ rejection in kidney, liver, and 
heart transplants; in dosages of 9±3 mg/Kg/day divided twice daily; and has been 
used with azathioprine and/or corticosteroids. It is a lipophilic cyclic 
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endecapeptide, isolated as an antifungal, from soil samples containing 
Cylindrocarpon lucidum BOOTH and Tolypocladium inflatum GAMS (fungi 
imperfecti). [43, 58] 
Pharmacokinetic problems due to incomplete, unpredictable and inadequate 
absorption of original formulation of CsA led to the introduction of new 
microemulsion formulation of CsA (Neoral), characterized by better absorption 
and a lower intra/inter-patient variability, allowing an improved long-term 
transplant outcomes. [43] 
Cyclosporin A is absorbed in the gut and peak plasma concentration is reached 
after 3-4 hours, passively diffuses through cell membranes of the following cells: 
erythrocytes (50%), lymphocytes (5%) and lipoproteins (40%), and 
approximately 5% remains free in the plasma. Then, CsA is metabolised in the liver 
microsomes, and excreted after 6 hours mainly via the bile, through the faeces. [43] 
The mechanism of action is the inhibition of production and release of interleukin 
II through its binding to immunophillin cyclophilin A and inhibiting the calcium 
dependent serine/threonine phosphatase calcineurin. At the same time, it inhibits 
selectively macrophage activation and IL-1 production, prevents the production of 
IL-1 receptors on T helper cells, inhibits IL-2 synthesis at low concentrations 
limiting clonal amplification of citotoxic T cell and it inhibits their ability to 
respond to IL-2 (probably blocking cell surface receptors). [43, 54, 58] 
The clinical use of CsA is associated to well documented side effects, such as: 
nephrotoxicity, hepatotoxicity, diabetes, hypertension, biliary calculus disease, 
epilepsy, tremors, plasmocytoma, squamous cell carcinoma of the lips, kaposi’s 
sarcoma, cephalalgy, sinusitis, conjunctivitis, hairy-leukoplakia, neurotoxicity, 
hirsutism, altered bone metabolism, gingival overgrowth and lingual fungiform 
papillae hypertrophy. [43] 
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2.3.3.1.2 Tacrolimus 
Tacrolimus (Prograf, Protopic) also termed with the synonym FK506, is used as 
a potent immunossupressive drug in liver and kidney transplant recipients; in 
dosages of 0,2 mg/Kg/day in 2 divided doses given every 12 hours. [54, 58] 
The mechanism of action is to suppress cellular immunity, namely, inhibits T-
lymphocyte activation, possibly by binding to an intracellular protein, FKBP-12. 
The FK506–FKBP12 complex, binds to calcineurin, like the CsA–cyclophilin A 
complex, also resulting in inhibition of IL-2 transcription. Tacrolimus is 10 to 100 
times more potent than CsA as an immunosuppressive agent. [54, 58] 
Although Tac and CsA have been associated with similar side effects in respect to 
nephrotoxicity, neurotoxicity and the induction of a diabetic state, it has been 
suggested that Tac could be associated with less frequent oral health problems, 
namely gingival overgrowth. [59] 
2.3.3.2 Prednisone 
Prednisone (Meticorten, Deltasone, Liquid Pred) also termed with synonyms 
deltacortisone and deltadehydrocortisone, is a systemic corticosteroid used in 
organ transplantation; in dosages of 5-60 mg/ day in divided doses given 1-4 
times/day. [58] 
Prednisone is a synthetic corticosteroid that is particularly effective as an 
immunosuppressant drug. The mechanism of action is to decrease inflammation by 
suppression of migration of polymorphonuclear leukocytes and reversal of 
increased capillary permeability, suppress the immune system by reducing activity 
and volume of the lymphatic system and suppress adrenal function at high doses. 
[58] 
It has short-term side effects like all glucocorticoids and mineralocorticoids, such 
as high blood glucose levels, especially in patients with diabetes mellitus or on 
other medications that increase blood glucose (such as tacrolimus); and fluid 
retention, respectively. Additionally, it can also includes insomnia, euphoria and, 
rarely, mania (in particular, in those suffering from Bipolar disorders I and II). For 
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long-term side-effects it could cause Cushing's syndrome, truncal weight gain, 
osteoporosis, glaucoma and cataracts, type II diabetes mellitus, and depression 
upon dose reduction or cessation. [58] 
2.3.3.3 Mycophenolate 
Mycophenolate (CellCept) is an immunosuppressant agent also termed with the 
synonym mycophenolate mofetil (MMF), which is used on prophylaxis of organ 
rejection concomitantly with cyclosporine and corticosteroids in patients receiving 
allogenic renal, cardiac or hepatica transplants; in dosages of 1 g twice daily. [58] 
The mechanism of action is by inhibition of purine synthesis of human 
lymphocytes and proliferation of human lymphocytes. [58] 
As with all immunosuppressants, a negative side effect is leaving the patient 
susceptible to infection. Among the most common side effects of MMF are high 
blood sugars and increased blood cholesterol levels. It is regularly noted other 
changes in blood chemistry such as hypomagnesemia, hypocalcemia, 
hyperkalemia, and an increase in BUN. [58]  
2.3.3.4 Rapamycin inhibitors 
Rapamycin (TOR) inhibitors, also known as mTOR inhibitors (mammalian target of 
rapamycin), are a new class of drugs, of which sirolimus (SRL) and everolimus 
(ERL) are examples, and are considered in CNI-free or CNI-sparing regimens for 
kidney transplant recipients, with the particular feature of offering renal 
protection because they are not nephrotoxic. [57, 60] 
2.3.3.4.1 Sirolimus 
Sirolimus (Rapamune) is an immunosuppressant agent used on prophylaxis of 
organ rejection in patients receiving renal transplants, in combination with 
cyclosporine and corticosteroids; in dosages of 2 mg/day. It is an antifungal 
macrolide with potent antiproliferative activities that results in an 
immunosuppressive effect. [58] 
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The mechanism of action is by inhibition of T-lymphocyte activation and 
proliferation in response to antigenic and cytokine stimulation. More precisely, it 
inhibits cellular proliferation stimulated by growth factor–driven signal 
transduction in response to alloantigens, however, it doesn´t inhibit the production 
of interleukin that results from antigen-induced T-cell activation. Nevertheless, it 
binds to the intracellular immunophilin FKBP12 and blocks the activity of the 
mammalian target of rapamycin (mTOR) with potent inhibition of downstream 
signaling and progression from the G1 to the S phase of the cell cycle. As a result it 
reduces the incidence of acute rejection after renal transplantation, without 
appearing to cause significant inherent nephrotoxicity.  However, when combined 
with CNI therapy, renal function often worsens as a result of potentiated 
nephrotoxicity. [52, 58] 
Sirolimus (SRL) is structurally similar to Tac, rather than CsA, and also binds to 
FKBP12, but the sirolimus–FKBP12 complex binds to and inhibits the mammalian 
target of rapamycin (mTOR), rather than calcineurin, resulting in inhibition of 
cytokine-mediated lymphocyte signaling, rather than cytokine production. [54] 
Among the more common side effects associated are hypertension, peripheral 
edema, chest pain, fever, headache pain, insomnia, hypercholesterolemia, 
hiperkalemia, hypokalemia, hypophosphatemia, hyperlipidemia, increased serum 
creatinine and symptoms related to gastrointestinal, genitourinary, hematologic, 
neuromuscular, skeletal and respiratory systems. [58] 
2.3.3.4.2 Everolimus 
Everolimus (Certican, Afinitor®) also termed with the synonym RAD-001, it is an 
inhibitor with potent immunosuppressive and antiproliferative effects that is 
currently used as an immunosuppressant to prevent rejection of organ transplants, 
and it is also used in patients with renal cell cancer for its antitumor activity. [49, 61] 
Recently, some attention has been paid to its highly effective action in preventing 
acute rejection in RTR, and additionally, much research has also been conducted 
on its use in a number of cancers. [49, 61] 
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Everolimus (ERL) is a derivative of SRL, it works similarly to SRL as an mTOR 
inhibitor, namely, it blocks growth factor-mediated proliferation of T cells, B cells 
and vascular smooth muscle cells and lately, like CNIs, it acts on cellular response. 
[52, 57] 
2.3.4 Dental and oral health of renal transplant recipients 
The dental and oral health of RTR will possibly reveal oral manifestations of the 
earlier CKD and oral complications of the transplantation. Among oral 
complications, stand out drug complications, particularly gingival overgrowth; oral 
infections, namely periodontitis, dental caries, candidiasis, viral infection and 
squamous cell carcinoma. It can also be noticed enlarged and friable “strawberry 
gums”, pathognomonic of Wegener’s granulomatosus which may be associated 
with alveolar resorption and increased tooth mobility, and the involvement of 
salivary glands. [35] 
Additionally, the examination of the perioral regions may reveal some features 
such as: pseudo-ruggades of systemic sclerosis, presenting as decreased maximum 
oral aperture on mouth opening; may be observed oral mucosal telangiectasia, as 
may widened periodontal ligament spaces; keratoconjunctivits sicca; xerostomia; 
difficulties with swallowing; impaired wound healing. [35] 
2.3.4.1 Drugs complications 
A drug complication is a disease or injury that develops during the treatment of a 
preexisting disorder, and frequently alters its prognosis. [3]  
One of the most frequent drug complications in mouth of RTR is gingival 
overgrowth (GO), and it is related to immunossupressive agents, namely, CsA. [35, 43, 
62] 
Immunosuppressants, and concurrent medical treatments, can lead to structural 
changes in the mouth, precipitating disease. Studies in the United Kingdom reveal 
that RTR are 2-3 times more likely to develop oral lesions when compared with the 
normal population, and often go less to the dentist. [35, 63] 
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2.3.4.1.1 Gingival overgrowth 
Gingival overgrowth (GO), also known as medication-associated gingival 
enlargement, refers to an abnormal growth of the gingival tissues secondary to the 
use of a systemic medication. Characteristically, neither the epithelium nor the 
cells within the connective tissue exhibit either hyperplasia or hypertrophy. It is 
known that gingival collagen constantly undergoes physiologic remodeling, and 
the process must be tightly controlled to maintain a constant volume of the 
gingival tissues. In GO this balance is disrupted, and the increased gingival size is 
due to an increased amount of extracellular matrix, predominantly collagen, 
because there are interferences with its remodeling, namely, the degradation 
process. [20, 64, 65] 
Gingival overgrowth is the main oral manifestation in transplant recipients who 
use calcineurin inhibitors. [66] In addition, GO may be exhibited by RTR who are 
taking CsA but also by patients with CKD medicated with phenyotoin or calcium 
channel blockers. In fact, the clinical presentation is very similar. In literature it is 
suggested that cyclosporine, phenytoin and nifedipine are all associated with 
calcium deregulation, which disrupts the normal collagen phagocytosis and 
remodeling process. If this is true, then the increased collagen does not occur from 
hyperplasia but from impaired collagen degradation and remodeling. [3, 20] 
Gingival overgrowth incidence and severity are increased when CsA and nifedipine 
are prescribed together. However, other calcium channel antagonists (verapamil) 
used in association with CsA do not have this effect. [35] 
Renal transplant recipients receiving Tac also can present GO, although most 
reported cases are associated with CsA. It is suggested that the use of Tac causes 
fewer oral side-effects than CsA, and further, replacing CsA with Tac can lead to a 
reduction or resolution of GO. [35, 43] 
Several associations of GO with age, sex, drug dosage, duration of therapy or 
interval since transplantation have been hypothesized. The introduction of 
alternative immunosuppressant drugs have been suggested to allow better long-
term transplant outcomes and a decrease in incidence of GO. [43] It should also be 
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taken into account the wide intra and inter-individual variability in the 
susceptibility of the CsA to induce GO. [43, 67] 
Gingival overgrowth mainly affects the labial interdental papillae, although, in 
more extensive cases, may involve gingival margins, lingual, and palatal gingivae 
(Figure 5). It is often limited to adherent gingiva, but it may extend coronally and 
interfere with occlusion, mastication and language, without necessarily altering the 
underlying periodontium. Additionally, it is related to difficulty in maintaining a 
good oral hygiene resulting in an increased susceptibility to infections, caries, and 
periodontal diseases. Furthermore, these consequences may have a psychological 
impact and may in turn influence compliance with medical therapy. [20, 35, 43, 68, 69] 
 
Figure 5. Gingival overgrowth. 
 
Gingival overgrowth pathogenesis related to CsA is still uncertain and is probably 
multifactorial. It has been suggested that CsA is able to alter the metabolism of 
gingival fibroblasts increasing IL-6 secretion, and also, that gingival fibroblasts 
produce considerable quantity of IL-6, especially after stimulation with bacteria or 
other cytokines. [43, 70-72] 
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Increased levels of IL-6 have been reported in RTR, but the cellular origin of IL-6 in 
GO related to CsA is unknown. [43, 73, 74] 
Gingival overgrowth, and its severity, is associated with risk factors such as: serum 
concentration and dosage of the drug, salivary concentration, time of 
administration, duration, age and sex, combinations of medications, genetic 
predisposition and oral hygiene. [43] 
Different therapeutic approaches for GO management have been proposed. The 
use of specific oral hygiene programs, surgical intervention and/or alternative 
pharmacological therapy has been reported. [43] 
Some authors consider that meticulous oral hygiene and frequent professional 
prophylaxis will help to reduce the effects of GO induced by CsA, however others 
report that additionally to oral hygiene, GO appears to be related significantly to 
the patient´s susceptibility. In fact, even with good oral hygiene some degree of 
gingival enlargement can be notice in susceptible individuals. Moreover, is 
generally accepted that rigorous oral hygiene often can limit the severity to 
clinically insignificant levels. [3, 20] 
Chlorhexidine mouthwash may be beneficial. It seems reasonable to convert 
patients with intractable gum disease from CsA to Tac if they require a CNI, or 
avoid the class altogether. However, the nature of organ transplants could not 
permit an alternative therapy or dose reduction. [35, 43] 
The need for surgical treatment needs to be carefully assessed. Surgery is normally 
performed for cosmetic/aesthetic requests before any functional need is showed. 
In cases where drug therapy must be continued for several years, psychosocial 
support needs to be considered with the purpose to reduce the frequency and 
extension of surgical interventions. [43] 
2.3.4.2 Oral infections 
Many systemic diseases like CKD can cause direct and indirect oral manifestations. 
The last one is the result of the host inflammatory or immune response 
modification and of host–parasite interaction balance disruption. This is crucial in 
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the pathogenesis of the two most prevalent oral infections – caries and periodontal 
diseases. [14] 
The oral cavity may harbour different microbial microenvironments of 
heterogeneous compositions. More than 300 different bacterial species have been 
described together with other microorganisms, such as viruses, fungi and 
mycoplasmas. The subgingival biofilm is a complex bacterial community adhering 
to the root surface separated from the oral cavity by the soft tissue pocket wall. 
Under these conditions, many bacterial species with a high potential virulence, 
such as Actinobacillus actinomycetemcomitans and Porphyromona gingivalis, are 
able to colonize, grow and cause periodontal tissue damage. Systemic diseases, 
which may influence the microenvironment of periodontal pockets, could 
potentially affect the composition of this subgingival biofilm. In fact, patients with 
ESRD exhibit increased susceptibility to gingivitis and periodontal disease. [3, 14] 
Fungal infection of the mouth is common. It is suggested that oral candidiasis will 
affect 20%-30% of RTR. [35] 
2.3.4.2.1 Periodontitis 
Periodontal diseases (PD) comprise a large group of disorders that affect the 
periodontium, which refers to specialized tissues that surround and support the 
teeth to the maxillary and mandibular bones, namely, gingival tissue, periodontal 
ligament, cementum and alveolar bone. PD has a multifactorial etiology and a 
prevalence of 20 to 50% on the worldwide population. [58] It includes gingivitis, 
chronic periodontitis and aggressive periodontitis. [75-78] 
Gingivitis (Figure 6), the most common form of gingival inflammation, is a 
reversible inflammatory reaction of the dento-gingival tissues to bacterial plaque 
accumulation, which resolves soon after the dental bacterial biofilm is disrupted. 
[75] 
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Figure 6. Gingivitis. 
 
Periodontitis, in contrast to gingivitis, is a chronic inflammatory reaction involving 
not only superficial gingival tissues but also periodontal ligament and the alveolar 
bone. Usually is an asymptomatic condition with gingival bleeding and swelling 
representing the most common clinical signs. In an advanced form of periodontitis 
that refers to a progressive destruction of the dental supporting tissues signs can 
be found such as: gingival recession, drifting of the teeth, mobility and 
suppuration. And if it is left untreated, periodontitis may result in a progressive 
deepening of the gingival sulcus associated to alveolar bone destruction up to the 
apex of the tooth which eventually ends with its loss (tooth exfoliation), which is a 
major public health problem that affects a large number of older adults. [75-79] 
Emerging evidence indicates that periodontitis is not a conventional infectious 
disease, but is an inflammatory disease triggered by host immune response to a 
constellation of periodontal biofilm-associated microorganisms. A dense 
mononuclear inflammatory infiltrate containing all cellular components acts 
between the infection and the targets of the disease (bone, connective tissue). 
Previous studies have shown that these inflammatory cells can infiltrate gingival 
tissues in an antigen-specific manner. [80, 81] 
In what concerns chronic periodontitis (CP), the most common type of PD, is 
defined by the American Academy of Periodontology as an infectious disease that 
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results in inflammation of the tissues that support teeth, progressive loss of 
attachment and bone loss. This process leads to pocket formation around the tooth 
and/or gum recession.  CP is initiated by the sub-gingival biofilm but its 
progression seems to be dependent of an abnormal host response to those 
organisms, generally accepted as the red complex, Porphyromonas gingivalis, 
tanerella forsythia and Treponema dentícola. [42, 82-84] 
To classified CP, Armitage classification can be used, which describes low levels of 
CP as slight periodontitis, although other terms can also be used including mild, 
early and initial periodontitis. [85] 
Aggressive periodontitis comprises a group of rare, often severe, rapidly 
progressive forms of periodontitis often characterized by an early age of clinical 
manifestation and a distinctive tendency for cases to aggregate in families. At the 
1999 international classification workshop the following major common features 
characterized it: non-contributory medical history, rapid attachment loss and bone 
destruction and familial aggregation cases. [86] 
Pathogenesis of periodontitis is described as a local inflammatory response elicited 
by the presence of subgingival pathogens. This is characterized by the formation of 
a local inflammatory infiltrate with exudation and migration of large number of 
leukocytes, involved in the first line of defense against bacterial pathogens, 
towards the affected area. Furthermore, this inflammatory response is exacerbated 
by the production of pro-inflammatory cytokines and prostaglandins. These are 
produced by a variety of cells involved in the response to the microbial invasion, 
such as monocytes/macrophages, neutrophils, lymphocytes, adipocytes and 
fibroblasts. The release of these substances into the bloodstream stimulates 
further recruitment of pro-inflammatory mediators and leukocytes at the local site. 
Cytokines such as IL-1 and IL-6 produced at the gingival sites might be dumped 
into the systemic circulation and stimulate a hepatic acute phase response to 
injury, and also stimulate haematopoiesis. All of this could cause damage to the 
structures that support the tooth, namely relocation of the junctional epithelium to 
the tooth root, destruction of the fibers of the gingival tissue, destruction of the 
periodontal ligament fibers and loss of alveolar bone support. Ultimately, these 
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damaged structures involve loss of bone height and eventually result in tooth loss. 
[42, 78, 84, 87] 
Longitudinal studies established that the amount of alveolar bone loss or the 
number of teeth present at the baseline may be used to predict further progression 
of the disease, these variables are measures of the disease itself and express the 
level of susceptibility of a given subject to periodontal diseases. Although they may 
be excellent predictors for further disease progression, they can clearly not be 
considered as risk factors. [86] 
A number of potential risk indicators that could be associated with PD have been 
suggested, such as increasing age, specific periodontal pathogens as 
Porphyromonas gingivalis, Tannerella Forsythis and Fusobacterium nucleatum, 
ethnic minorities, low socio-economic status, male gender and stress. Additionally, 
recent evidence suggests that common cardio-metabolic risk factors, including 
body weight, dyslipidemia and hypertension, are also associated with increased 
odds of prevalence of periodontitis. [78] 
In what concerns cigarette smoking there is a considerable body of evidence 
demonstrating the association of periodontal destruction with it. The main effect of 
smoking is on the immune and inflammatory response and it is suggested that it 
results in the decrease of clinical signs, namely, gingival inflammation such as 
redness and bleeding. It is also suggested that smokers have a greater risk of 
exhibiting more periodontal attachment loss, larger number of deep periodontal 
pockets, higher mean probing pocket depth and more extensive and severe 
alveolar bone loss. Substantial epidemiological data indicate that smokers have 
fewer teeth, a higher prevalence of edentulism and a greater incidence of tooth loss 
than non-smokers.  Another possible effect of smoking is on the microflora, 
however, its effect is inconclusive. [88, 89] 
Periodontal diagnosis is predominantly based on clinical and radiographic 
measures. [90, 91] 
In what concerns the measurement of periodontal health the accurate assessment 
is often performed by a trained examiner, using a periodontal probe. [90, 91] 
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Periodontal probes are used for this examination to help assess pocket depth and 
loss of attachment around each tooth and the presence of gingival bleeding. [90-92]  
This is then confirmed by radiographic assessment of the alveolar bone levels of all 
dentition. [90, 91] 
The Florida Probe introduced by Gibbs and co-workers [93] is an automated 
periodontal probe that has shown to be more reproducible than manual probing in 
a number of studies. At present this probe is considered the “golden standard” of 
the automated probes based on the extensive research on the validity of it. [91] 
Clinical attachment level is defined as the distance from the cement-enamel 
junction to the tip of the probe. [86, 92] Attachment loss is measured (to the nearest 
mm) by simple probing by identifying the cemento–enamel junction and 
measuring the distance to the base of the pocket. [92] Probing depth is defined as 
the distance from the soft tissues margin to the tip of the probe. [86, 92] All teeth are 
examined. Third molars are excluded from analysis. [92] 
Cemento-enamel junction is a fixed point that does not change; it refers to an 
anatomical border identified on a tooth that is the location where the enamel, 
which covers the anatomical crown of a tooth, and the cementum, which covers the 
anatomical root of a tooth, meet. This border is usually the location where the 
gingival tissue attaches to a healthy tooth by fibers called the gingival fibers. 
Because the bone level in health is approximately 2 mm apical to the CEJ, clinical 
attachment levels provide a reliable indication of the extent of bone support for a 
tooth. [86] 
The recording of the probing depth is not considered a reliable indicator of the 
extent of bone support, because these measurements are made from the gingival 
margin which changes with tissue swelling, overgrowth, and recession. [91, 92] 
Additionally, in patients with untreated periodontal disease, remaining calculus, 
plaque and over contouring of restorations might also influence probing depth. [91] 
In what concerns gingival bleeding during probing depth, bleeding on probing 
(BOP), it is a sign of inflammation. Bleeding can be visible immediately when a site 
is probed, or it may not be evident until about 10 seconds. BOP correlates with 
STUDY OF ORAL HEALTH STATUS IN RENAL TRANSPLANT RECIPIENTS 
Introduction 
 
 
34 
gingival inflammation and is widely used in risk evaluation of periodontal disease 
progression. However, it has been shown that many sites with no progression of 
periodontal disease exhibited bleeding and thus, BOP has been considered a poor 
prognostic indicator for attachment loss in spite of its high degree of specificity. 
The relationship between BOP and periodontal progression is difficult to establish, 
as the results may be easily confounded by other factors such as smoking. It has 
been observed that smokers have less gingival bleeding when compared with non-
smokers. [79, 94] 
The periodontal status of each subject is assessed on the basis of the amount of 
CAL [92]. Two terms commonly used synonymously and abbreviated as CAL are 
clinical attachment level and clinical attachment loss. Clinical attachment loss is 
defined as the apical migration of the periodontal attachment from a reference 
point, which was supposed to be the normality. [92] Severity is characterized on the 
basis of the degree of attachment loss recorded in terms of the following codes: 
Health: Periodontal attachment loss 0 mm; Slight: Periodontal attachment loss 1 or 
2 mm; Moderate: Periodontal attachment loss 3 or 4 mm; Severe: Periodontal 
attachment loss +5 mm or more. [92] Extent is characterized as ‘Localized’ = 30 % of 
sites involved, and ‘Generalized’ = ≥ 30% of sites involved. [92] 
Nevertheless, clinical measurements provide us with an insensitive, retrospective 
analysis of what has already occurred, but allow us to diagnose disease based on 
its natural history. Measures of clinical attachment levels, by use of conventional 
probes, are only sufficiently sensitive indicators of periodontitis when as much as 
20-30% of attachment has already been lost. Current technological improvements 
in probing measurements and radiographic assessment may increase sensitivity in 
this area. [78] 
One of the challenges of periodontal practice is determining which patients with 
low levels of periodontal clinical attachment loss are most at risk for developing 
additional clinical attachment loss. This challenge extends to public health 
dentistry where population-based strategies are needed to reduce risk of 
periodontal infections that affect the dentition and can have an impact in systemic 
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health. CAL is considered a clinical predictor of periodontal disease progression. 
[85] 
There have been signs that periodontitis may contribute to chronic systemic 
disease. [42] In fact, accumulating evidence suggests that the local inflammatory 
and/or infectious burden associated with periodontitis predispose to systemic 
diseases, namely, cardiovascular disease (CVD), CKD and diabetes. Indeed, 
periodontal status has been suggested to affect CVD traditional and newly risk 
factors, and it has been included in CKD multiple risk factors. [42, 75, 87, 95-98] 
The explanation offered for this connection is that periodontal pathogens may 
circulate in the bloodstream and promote damage to blood vessel endothelium and 
atherosclerosis. It is plausible that such damage occurs not only in the endothelia 
of the heart and brain but also in kidney endothelium. [42] 
Other explanation is that, similarly to acute bacterial infections, the persistent 
periodontal inflammatory state might have a repercussion on the total numbers of 
circulating neutrophils, because of increased bone marrow output or mobilization 
of the marginal granulocyte pool. Whether the increased number of leukocytes is 
mainly due to bacteremia or to excessive local production of inflammatory 
mediators remains unclear. [87] 
Common risk factors for periodontitis and CVD have been described, as well as 
similar pathways have been proposed that include occurrence of transient 
bacteremia, elevation of inflammatory mediators in the systemic circulation in 
response to bacterial factors, endothelial and smooth muscle cell activation and 
molecular mimicry between bacterial and self-antigens. [87, 99] However, results 
might reflect possible confounders. [99] 
In what concerns periodontitis and CKD, it is known that various chronic and acute 
infections are able to incite an inflammatory response in the kidney called 
glomerulonephritis, and periodontitis could be another one. Additionally, some 
researchers have shown the relation between periodontitis and kidney disease. [42, 
100, 101] 
STUDY OF ORAL HEALTH STATUS IN RENAL TRANSPLANT RECIPIENTS 
Introduction 
 
 
36 
The potential role of periodontal disease as a possible chronic source of infection 
and inflammation is supported by findings indicating its association with elevated 
serum levels of C-reactive protein (CRP) [99, 102, 103]. Recent studies have shown an 
association between high levels of CRP and interleukin-6 (IL-6) with periodontitis, 
an association that decreases after periodontal treatment [100, 104]. The association 
between periodontitis and systemic inflammatory response, determines the 
recently inclusion of periodontitis as a nontraditional risk factor for CKD. [99, 100, 102] 
Despite all that has been published these associations are still not fully understood 
and are source of controversy, so further investigation is necessary. 
2.3.4.2.2 Dental Caries 
Dental caries is the most prevalent dental disease affecting human race although 
the prevalence of dental caries has significantly reduced; it is still a major problem. 
[105-107] The etiology and pathogenesis of dental caries are known to be 
multifactorial. [105-107] 
Dental caries results in destruction of tooth structure by acid-forming bacteria that 
are found in dental plaque, which is an intraoral biofilm. The infection results in 
loss of tooth minerals, which begin on the outer surface and can progress through 
the dentin to the pulp, and this, can compromise the vitality of the tooth. [105, 106] 
For RTR patients the immunosuppression status results in an increased risk of 
infectious complications and dental caries may represent an open door for 
bacteria. Therefore, dental caries treatment is indicated before patients start 
immunosuppression, and routine attendance to the dentist is advised for 
prevention. [108, 109] 
An important factor for dental caries development and tooth demineralization/ 
remineralization rate is the secretion rate and quality of saliva. [106] 
2.3.4.2.3 Oral Candidiasis 
Oral candidiasis is a common fungal infection of the mouth that could affect 20% to 
30% of allograft recipients. It refers to an opportunistic infection caused by 
Candida albicans, a ubiquitous fungal organism that is part of the no
microbiota. [110] 
In immunocompromised patients the presence of Candida albicans in the mouth 
can predispose to infections in other systems as esophageal, gastrointestinal, 
respiratory and urinary. [110
invasive form of infection with significant morbidity and higher risk for 
disseminated infection and eventually fatal. 
were preceded by oral candidiasis or colonization
This infection may present as angular cheilitis, pseudomembranous or 
erythematous ulceration 
found in conjunction with occult esophageal infection and a history of odynophagia 
should alert physicians to the possibility of systemic candidiasis. 
Figure 
 
Prevention with antifungal lozenges or 
post-transplant period (when corticosteroid doses may be highest). Treatment 
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depends on severity; lozenges may cure mild infections, but oral anti-fungals may 
be required, particularly if esophageal infection is suspected. [35] 
2.3.4.2.4 Viral infection 
In literature it has been reported that in RTR herpes simplex virus, 
cytomegalovirus and papilloma virus could cause viral infections in the mouth. 
Herpes simplex virus is a common and often troublesome infection in RTR, which 
frequency has been reduced by the use of antiherpetic agents, such as acyclovir. 
Not uncommonly Kaposi’s sarcoma occurs and it could be caused by human herpes 
virus type 8. Cytomegalovirus infection often manifests with oral ulceration, 
usually in the context of tissue-invasive disease elsewhere. [35] 
2.3.4.3 Squamous cell carcinoma 
Squamous cell carcinoma is one of the most common cancers and usually arises 
from mutated ectodermal or endodermal cells lining body cavities. Therefore, it 
can develop in a large number of organs and tissues, including the skin, lips, 
mouth, esophagus, urinary bladder, prostate, lung, vagina and cervix, among 
others. Squamous cell carcinoma of the lip is considerably more common in RTR 
than in the normal population. [20, 35] 
The cause of oral squamous cell carcinoma is multifactorial. No single causative 
agent or factor (carcinogen) has been clearly defined or accepted, but both 
extrinsic and intrinsic factors may be at work. Extrinsic factors include tobacco 
smoke, alcohol, syphilis and sunlight, which is only for lip vermilion cancers. [20] 
Additionally, the papillary squamous cell carcinoma, which is a rare variant of the 
head and neck squamous cell carcinoma, is more frequent in patients with 
immunosuppression including those who have received a transplant. Established 
etiological factors can include tobacco smoking, heavy alcohol abuse and human 
papillomavirus infection. [111] 
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2.3.5 Dental management of renal transplant recipients 
Renal transplant recipients may have special dental management needs, which 
may be similar to CKD patients, because they are affected by corticosteroid and 
other immunosuppressive treatments, hemorrhagic tendencies, anemia, impaired 
drug excretion, hypertension, hepatitis B or C carriage, underlying causes of ESRD 
namely, diabetes mellitus. Among the most important dental management needs 
are the monitorization of blood pressure, screening for bleeding disorders and 
anemia, and prompt treatment of oral infections or antibiotic prophylaxis.  Any 
abnormal values should be discussed with the physician. [3, 20] 
When surgical procedures are undertaken, meticulous attention to good surgical 
technique is necessary to decrease the risks of excessive bleeding and infection. 
Alterations in drug dosage may be needed according to the amount of kidney 
function that is present, and an important concern are the drugs that are excreted 
primarily by the kidney, or that are nephrotoxic, such as acyclovir, 
aminoglycosides, aspirin, nonsteroidal anti-inflammatory drugs, tetracycline and 
acetaminophen. [3] 
Dental care should be considered a standard part of the management of RTR. Its 
goals are to restore the mouth to the healthiest condition possible and to eliminate 
possible sources of infection. Routine dental care should be a common practice, 
should begin before listing for transplantation and should consist in a detailed 
dental assessment, treatment of gum disease, caries and impacted molars. [3] 
 
3 Saliva as a diagnostic tool for assessment of oral health 
In healthy individuals saliva fluid covers the tissues in the mouth and is critical to 
the preservation and maintenance of oral health. [21, 112-115] 
Characteristically, saliva is a very dilute fluid composed for more than 99% of 
water. [115, 116] Whole saliva is a mixture of the secretions from the parotid, 
submandibular, sublingual and minor salivary glands and gingival crevicular fluid. 
[117] Major salivary glands contribute for most of the secretion volume and 
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electrolyte content of saliva, whereas minor salivary glands contribute with little 
secretion volume and with most of the blood-group substances. Its normal 
composition is characterized by a variety of electrolytes, such as sodium, 
potassium, calcium, magnesium, bicarbonate and phosphates; immunoglobulins, 
proteins, enzymes, mucins; and nitrogenous products, like urea and ammonia. [115, 
116] 
Salivation is initiated by the salivary centers in the medulla oblongata, which 
receive afferent signals from the sensory terminals of the oral and nasal cavities 
and from the higher centers in the brain. [117] The secretion of saliva is regulated by 
the autonomic nervous system and its composition follows circadian rhythms. [117] 
Water and electrolyte secretion are mainly controlled by parasympathetic activity, 
whereas protein synthesis and exocytosis are mainly controlled by sympathetic 
activity. [118, 119] 
Salivary function maintains oral health and creates an appropriated ecologic 
balance. It has 5 major functions: lubrification and protection, buffering action and 
clearance, maintenance of tooth integrity, antibacterial activity, taste and digestion. 
[21, 32, 113, 115, 120-122] 
Interestingly, altered concentrations of various salivary electrolytes and ions may 
compromise several salivary functions related to remineralization, maintaining 
buffering capacity, taste mediatory role and digesting ability. [115, 116] 
For the last ten years, researchers have shown increasing interest in using saliva to 
diagnose several diseases, to monitor therapeutic and illicit drugs and hormone 
levels, and to determine antibodies that protect the body from infectious 
processes. [114, 115] 
Nowadays, saliva is already used to aid the diagnosis of dental diseases, in 
situations like: caries risk assessment, periodontal disease genotypes and markers 
identification, salivary gland diseases and dysfunction, and Candida albicans 
infections. [114, 115] 
Some studies have demonstrated the usefulness of saliva and gingival crevicular 
fluid for the diagnosis of periodontitis. [123, 124] Whole saliva sampling is far easier, 
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noninvasive and cheaper than gingival crevicular fluid collection. [123] In addition, 
collection of saliva is less costly and time-consuming. [123] Saliva contains many 
enzymes and some inflammatory markers. [123] These enzymes in serum have been 
routinely examined for the screening of systemic disease. [123] Therefore, no 
specific laboratory devices are necessary, and this approach is considered to be 
suitable for public health use. [123] 
The value of saliva will certainly continue to increase because it is an easily 
collected, noninvasive source of information. Additionally, it might be used in 
clinically difficult situations, such as dealing with children, physically impaired and 
anxious patients, where collection of blood samples would be a complex task. [114, 
115] 
 
4 Aims 
The study aims to evaluate the differences in the oral health status of renal 
transplant recipients administrated with Cyclosporin A, Tacrolimus or Everolimus, 
and compare it with patients on hemodialysis (pre-transplant) and healthy 
controls (living kidney donor). Furthermore, when observing alterations among 
groups, oral microbiota, salivary and serum biochemical parameters will be 
studied. 
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Chapter II – Material and 
Methods 
 
 
 
1 Subjects 
Renal transplant recipients receiving CsA, Tac or ERL as maintenance 
immunosuppressive regime and patients undergoing hemodialysis, 18 to 70 years 
old, followed-up in the post-transplant outpatient clinic of the Nephrology 
Department of “Hospital de S. João” were included in the study. All RTRs were 
taking corticosteroids (metilprednisone/prednisone) and an antimetabolite 
(mycophenolate mophetil). Living kidney donors were recruited as healthy control 
group. Patients with diabetes, active systemic infection and those who possess less 
than 8 of the ten most anterior teeth in the upper or lower dental arches were 
excluded. The study was approved by the Ethics Committee of “Hospital de S. João”. 
All participants were recruited voluntarily after receiving detailed information on 
the study protocol and written informed consent was obtained in all cases. 
Demographic variables including age, gender, literacy, body mass index, time since 
transplant and pharmacological data were recorded for all subjects. A physician, 
blind to the transplantation status and immunosuppressive treatment, evaluated 
the oral health status in all patients through oral examination carried out by a 
single calibrated dentist. The calibration was carried out about 4 weeks before the 
start of the study in the Department of Oral Medicine and Oral Surgery, Faculty of 
Dentistry, University of Porto. Blood samples were collected after 12 hours 
overnight fasting on the morning of the oral examination. The serum levels of the 
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immunosuppressor were measured. Cyclosporin A and Tac blood levels were 
measured using using chemiluminescent microparticule immunoassay (Abbot 
Architect I System analyzer, Abbott, IL, USA) whereas ERL blood levels were 
measured using fluorescent polarization immunoassay (Seradyn Innfluor 
Certicann adapted to an Abbott TDx Flex analyser, Abbott, IL, USA). Glomerular 
filtration rate (GFR) was estimated using the Cockcroft-Gault formula [125]. An 
online application was built for patient's data collection and storage. This included 
two independent input forms, one intended for the general characterization of 
clinical and demographic data and the other for the oral evaluation status. Data 
were stored in a common database, aggregated and then exported for further 
statistical analyses. 
 
2 Oral evaluation 
Oral hygiene habits were evaluated by inquiring the participants about the daily 
tooth brushing habits and how often the toothbrush was changed yearly. Oral 
symptoms were evaluated by asking the participants if they had the feeling of a dry 
mouth during the day and if they had the feeling of a bad breath during the day. 
Oral hygiene was assessed using the Visible Plaque Index (VPI) and the Gingival 
Index. The VPI [126] was assessed in four sites of each tooth (mesio-buccal, mid-
buccal, disto-buccal, mid-lingual); the percentage of the examined sites with visible 
plaque ranged from 0% to 100%. The gingival index [127] is scored as follows: 0 = 
normal gingiva; 1 = mild inflammation, slight change in color, slight edema, no 
bleeding on probing; 2 = moderate inflammation, redness, edema, and glazing, 
bleeding on probing; 3 = severe inflammation, marked redness and edema, 
ulceration, tendency to spontaneous bleeding. 
For each participant the number of decayed (D), missing (M) and filled (F) teeth 
was recorded and the DMFT index was calculated following the World Health 
Organization recommendations. [126, 128] In addition, a full-mouth periodontal 
examination was performed for all the teeth present in the oral cavity, excluding 
the third molars, using a dental mirror, an explorer and the Florida Probe 
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introduced by Gibbs and co-workers [93]. The clinical attachment loss (CAL) and the 
bleeding on probing (BOP) [127, 129] were recorded. CAL and BOP were assessed at 6 
sites around each tooth (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, 
mid-lingual, disto-lingual). CAL was expressed as the distance in mm from the 
cemento-enamel junction to the bottom of the gingival pocket. [15] BOP was scored 
positive if a site bled after pocket probing within the time interval used for the 
buccal and lingual measurements of a quadrant. [76] 
Gingival enlargement (GE) was measured per sextant using the Aas Index. [130]. We 
have followed a visual index, like Greenberg and co-workers [131], instead of an 
approach based on alginate impressions to avoid overburdening study participants 
who were receiving a full-mouth periodontal examination. Grade 0: no GE; grade I: 
slight or moderate GE; Grade II: marked GE; Grade III: severe GE; grade IV: very 
severe. Each sextant was graded according to the most severe site. A subject was 
classified as having GE when at least one interdental papilla with GE grade I was 
present in at least one sextant. 
Additionally, whole saliva was collected in a quiet room over 5 minutes, between 
8:00 to 12:00 AM to minimize the circadian rhythm effects, and at least 2h after 
eating, tooth brushing, mouth washing or smoking. Salivary secretion was 
stimulated with paraffin pellets (Ivoclar vivadent, NY, USA) and the participants 
were asked to spit into a sterile tube. The total amount collected over a 5-min 
period was registered, enabling the salivary flow rates (ml/min) to be calculated.  
The salivary pH was measured immediately after saliva collection using a pH 
indicator paper (5.0-8.0, Duotest, Germany). 
 
3 Oral fungi characterization 
Fungi quantification and identification was performed at FMDUP (classical 
microbiological methodology) and IPATIMUP (molecular biology methodology). 
For fungi’ isolation and quantification, a selective and differential culture medium 
was used: CHROMagar CandidaTM. The stimulated saliva samples were serially 
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diluted with 0.9% sterile NaCl solution until 10-2 and immediately plated in 
triplicate. Afterwards, plates were incubated aerobically for 48h at 37°C. Total 
number of colonies was counted, and the quantification results expressed in colony 
forming units (CFU) per ml of saliva (CFU/ml). The lower limit of detection was 
102 CFU/ml. 
Identification of Candida albicans, C. tropicalis and C. krusei was possible due to the 
specific colour of the colonies (green, metallic blue, pink, respectively). The other 
non-identified isolates were identified using a sequencing approach. Single 
colonies of non-identified yeast isolates were cultured on Sabouraud agar for 24h 
at 37ºC. A sodium hydroxide based method was used to extract DNA from yeasts 
following the protocol available at 
http://www.aspergillus.org.uk/indexhome.htm?secure/laboratory_protocols. 
The identification of these microorganisms was based on the sequence analysis of 
18s and internal transcribed spacer (ITS) regions employing a group of specific 
primers – EF3, EF4, fung5, ITS1-F, ITS4. [132, 133] The PCR reactions were performed 
in a Thermo-Hybaid-PX2 thermal cycler. Amplification products were visualized in 
a polyacrilamide gel and a silver-staining followed. Sequence analysis was used to 
identify gene fragments using a Genetic Analyzer ABI-Prism-3100 (Applied 
Biosystems). Genomic data obtained was compared with a database that comprises 
a large collection of yeast sequences of 18s and ITS regions from Genbank1. 
 
4 Saliva analysis 
Biochemical parameters analysis was performed using an automatic analyzer, 
Pentra C200 (Horiba Medical, Montpellier). 
For unstimulated saliva it was evaluated: alkaline phosphatase (ALP) U/L, 
aspartate aminotransferase (AST) U/l, L-lactate dehydrogenase (LDH) U/L, C-
reactive protein (CRP) mg/l, LDL-Colesterol mg/dl, triglycerides mg/dl, uric acid 
mg/dl, urea mg/dl, creatinine mg/dl, total proteins mg/l, albumin mg/l, calcium 
                                                        
1       (http://www.ncbi.nlm.nih.gov/genbank/). 
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mg/dl, Iron mg/l, magnesium mmol/l, phosphorus mg/dl, sodium ISE(U)-Na, 
potassium ISE(U)-K,  clorum ISE(U)-Cl. 
And for stimulated saliva it was evaluated: amylase, Immunoglobulin A CP, 
Immunoglobulin G CP, LDH ifcc, calcium mg/dl, Iron mg/l, magnesium mmol/l, 
phosphorus mg/dl, sodium ISE(U)-Na, potassium ISE (U)-K,  chlorine ISE(U)-Cl. 
In brief, sodium, potassium and chloride were evaluated by potentiometry using 
ion selective electrodes. UV using phosphomolybdate detected phosphate and 
calcium was determined by a photometric test, using ortho-cresolphthalein 
complexone. In addition, α-amylases were detected by an enzymatic photometric 
test, using as substract 4,6- ethylidene- (G7)-p-nitrophenyl-(G1)- α-D-
maltoheptaoside (EPS-G7).  
Several methods were used to evaluate the following parameters: ALP by the 
photometric method in according to IFCC; AST by UV method according to IFCC 
without pyridoxal phosphate; LDH by optimized method according to DGKC; LDH 
ifcc according to IFCC; CRP by turbidimetric method; LDL-cholesterol by 
homogenous method for direct determination of LDL; triglycerides by PAP 
enzymatic method; uric acid by Trinder method; urea by enzymatic test UV 
“Urease-GLDH”; creatinine by Jaffé method; total proteins by photometric method 
with Red Pyrogallol; albumin by colorimetric BCG (bromocresol green) method; 
iron by photometric test with Feren; magnesium with photometric test with Blue 
Xilidil; IgA and IgG by turbidimetric method. 
 
5 Blood analysis 
Blood collection was taken on the morning of the oral examination. Venous blood 
samples were taken from subjects after fasting for 12 h overnight. 
The following blood parameters were consulted from medical records for all 
participants, namely 1) hemogram: hemoglobin (g/dl), hematocrit (%),leucocytes 
(%), neutrophils (%), eosinophils (%), basophils (%), lymphocytes (%), monocytes 
(%), platelets (x109/l); 2) general chemistry: total cholesterol (mg/dl), HDL 
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cholesterol (mg/dl), LDL cholesterol (mg/dl), triglycerides (mg/dl), glucose 
(mg/dl), urea (mg/dL), acid uric (mg/dl), creatinine (mg/dl), calcium (mEq/l), 
sodium (mEq/l), potassium (mEq/l), chloride (mEq/l) inorganic phosphorus 
(mg/dl), iron (ug/dl), magnesium (mmopl/l), transferrin (mg/dl), ferritin ng/ml, 
iron /transferrin x 70.9 (%); 3) proteins: total proteins (mg/l), C-reactive protein 
(mg/ml), albumin (mg/l), aspartate aminotransferase (U/l), alanine 
aminotransferase (U/l), alkaline phosphatase (U/l); 4) immunoglobulins: 
immunoglobulin A (mg/dl), immunoglobulin G (mg/dl), immunoglobulin E 
(mg/dl); 5) complement: C3c (mg/dl), C4 (mg/dl); 4) endocrinology: vitamin D 
(pg/ml), parathyroid hormone (PTH-I) (pg/ml). 
 
6 Ratio of biochemical parameters in saliva and blood 
Ratio was calculated for each biochemical parameter studied. This value 
represents the quotient between the median of a parameter in saliva and the 
median of the same parameter in serum. 
 
7 Statistical analysis 
The categorical variables were described through absolute and relative 
frequencies (%) and analyzed by Chi-square independence test. Continuous 
variables were described using mean ± standard deviation (SD) and analyzed by 
one-way ANOVA when following a normal distribution. When continuous variables 
did not follow a normal distribution they were described using median, mean± 
standard deviation and analyzed by Kruskall-Wallis or Mann-Whitney test. A level 
of 0.05 was considered significant. The analyses were performed using the 
statistical analysis program SPSS® v.17.0 (Statistical Package for Social Sciences). 
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Chapter III – Results 
 
 
 
1 Subjects 
A total of 88 RTRs receiving CsA (n=29), Tac (n=36) or ERL (n=23), 23 patients 
undergoing HD (n=23) and 13 LKDs were included in the study. The CsA, Tac and 
ERL daily dosages and corresponding blood levels are given in Table 1. The pre-
transplant dialysis vintage did not differ among the three groups of RTRs (Table 1). 
The median time on hemodialysis (min-max) was 53(24-204) months. 
Statistically significant differences were observed in the time after transplant 
among the three groups of RTRs (Table 1). Through multiple comparisons tests are 
observed differences and reveal that RTRs receiving ERL presents median values 
significantly higher when compared with the other two RTRs groups. This result is 
illustrated in the graph of Figure 8. 
Both serum creatinine levels and GFR were similar between RTRs receiving CsA, 
Tac and ERL (Table 1). As expected, renal function was well preserved in LKD 
group [serum creatinine 0.8 mg/dl (0.5-1.5); GFR 84 ml/min (68-207)]. 
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Table 1. Daily dosage and corresponding blood levels of CsA, Tac and ERL. Renal 
history among RTRs receiving CsA, Tac and ERL. 
 CsA 
(n=29) 
Tac 
(n=36) 
ERL 
(n=23) 
p 
Immunossupressor therapy 
Dosage (mg/day) 
200 
(100-400) 
4.8 
(1.5-12.0) 
2.0 
(0.5-3.0) 
- 
Blood level (ng/ml) 143.99±62.09 8.21±2.39 7.27±1.85 - 
Renal history 
Time after transplant 
(months) 
11 
(0-201) 
17 
(0-152) 
119 
(20-216) 
<0.001† 
Glomerular filtration 
rate (mL/min) 
52 
(23-74) 
54  
(11-128) 
50  
(21-110) 
0.641† 
Pre-transplant dialysis 
vintage (months) 
45 
(8-174) 
36 
(3-87) 
26 
(4-62) 
0.111† 
Values are presented as median (min-max) except blood levels presented as mean ± standard 
deviation. Testing of group differences by †Kruskall-Wallis test. 
 
 
Figure 8. Distribution of time after transplant by group. 
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The RTRs receiving Tac were younger than RTRs receiving CsA and ERL, or HD and 
LKD groups (Table 2). This result is illustrated in the graph of Figure 9. 
The prevalence of female gender was higher in LKD group in comparison with the 
others studied groups (Table 2). This result is illustrated in the graph of Figure 10. 
No significant differences were observed in body mass index, systolic blood 
pressure, diastolic blood pressure and heart rate, among all the studied groups 
(Table 2). The smoking habits, both current and past did not differ significantly 
among all the studied groups (Table 2). 
Table 2. Age, gender, literacy, body mass index, blood pressure, heart rate and smoking 
habits among RTRs receiving CsA, Tac and ERL, HD and LKDs groups. 
 CsA 
(n=29) 
Tac 
(n=36) 
ERL 
(n=23) 
HD 
(n=23) 
LKD 
(n=13) 
p 
Age (years) 55(8) 39(9) 50(11) 52(8) 44(9) <0.001# 
Gender      0.002* 
Male 
15 
(51.7) 
19 
(52.8) 
16 
(72.7) 
17 
(73.9) 
1 
(7.7) 
 
Female 
14 
(48.3) 
17 
(47.2) 
6 
(27.3) 
6 
(26.1) 
12 
(92.3) 
 
Literacy 
Sixth grade 
11 
(78.6) 
10 
(66.7) 
6 
(66.7) 
4 
(100) 
3 
(75) 
- 
Higher than sixth 
grade 
3 
(21) 
5 
(33) 
3 
(33) 
0 1 
(25) 
- 
Body mass index  24(2) 24(4) 25(4) 26(1) 23(2) 0.357# 
Blood pressure 
Systolic  137(12) 134(14) 133(15) 131(15) 123(20) 0.428# 
Diastolic  81(9) 80(11) 77(13) 80(9) 68(11) 0.261# 
Heart rate 75(15) 80(12) 75(11) 82(15) 63(2) 0.160# 
Smoking habits 
Current smoking 5(17) 16(44) 6(29) 8(35) 4(31) 0.225* 
Past smoking 15 (52) 19(53) 11(52) 15(65) 6(46) 0.810* 
Values are presented as number (%) except age and body mass index presented as mean ± 
standard deviation. Testing of group differences by # one-way ANOVA or *chi-square test. 
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Figure 
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9. Distribution of age by group. 
10. Distribution of gender by group. 
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2 Oral health status 
The oral health evaluation data among RTRs, HD patients and LKDs is given in 
Table 3. No significant differences were observed in oral hygiene habits and oral 
symptoms among the three groups (Table 3). In addition, both visible plaque index 
and DMFT index did not differ among the three groups (Table 3). No differences 
were found for bleeding on probing among the three groups (Table 3). Concerning 
clinical attachment level, positive cases for gingival enlargement were excluded, 
and no differences were found among the three groups (Table 3). 
The results of gingival enlargement (Figure 11) failed to detect statistically 
sufficient evidence on the association with the groups ((χ2=2.588a2 , df=2, p>0.05). 
Nevertheless, the graph of Figure 12 illustrates a GE trend to be associated to RTRs 
group. Regarding GI, no statistical analysis could be performed due to the reduced 
number of cases in gingival index scores. The graph of Figure 13 illustrates a 
similar distribution of GI scores across groups. 
Unstimulated and stimulated saliva pH did not differ among the studied groups 
(Table 3). Statistically significant differences were observed in both unstimulated 
and stimulated flow rate among the three groups (Table 3). Through multiple 
comparisons tests are observed differences in both unstimulated and stimulated 
flow rate. These differences reveal that HD patient’s present median values 
significantly lower when compared with RTRs and LKDs groups. These results are 
illustrated in the graphs of Figures 14 and 15. 
No statistically significant differences were observed in the distribution of 
unstimulated (Kruskall-Wallis test, Z=1.198, p=0.113) and stimulated (Kruskall-
Wallis test, Z=1.246, p=0.090) saliva flow rate in the individuals with or without 
the feeling of a dry mouth, as can be illustrated by the graphs in Figure 16. Even 
though the individuals with the feeling of a dry mouth presented a median values 
of unstimulated and stimulated saliva flow rate lower than those who do not have 
this feeling. 
                                                        
2 a. 2 cells (33,3%) have expected count less than 5. The minimum expected count is 1.11. 
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Table 3. Oral hygiene habits, oral symptoms, teeth evaluation, periodontal evaluation 
and saliva flow rate and pH evaluation in RTRs, HD and LKDs groups. 
 
RTR 
(n=88) 
HD 
(n=23) 
LKD 
(n=13) 
p 
Oral hygiene habits 
Daily tooth brushing <2 
times per day 
28(37.3) 11(57.9) 5(38.5) 0.260* 
Change toothbrush <4 
times per year 
33(37.9) 3(13.0) 5(38.5) 0.255* 
Oral symptoms 
Dry mouth 44(59.5) 13(68.4) 6(46.2) 0.452* 
Bad breath 45(60) 14 (73.7) 10(76.9) 0.326* 
Teeth evaluation 
Visible Plaque index 94(87.4±18.7) 100(90.5±15.1) 85(83.2±13.7) 0.138† 
Decayed median 1(2.5±3.6) 1(2±2.2) 1(2.2±2.3) 0.792† 
Missing  median 0(1.5±2.6) 0(1.5±2.9) 1(2.6±3.3) 0.248† 
Filled 6(7.3±6) 7(8±7.7) 11(11.6±8.2) 0.184† 
DMFT index 11(11.1±7) 10(11.5±8.6) 18(16.4±8) 0.086† 
Periodontal Evaluation 
Bleeding on probing 
6 
(14.1±19.6) 
4 
(12.3±21.9) 
5.5 
(9.9±10.5) 
0.753† 
Clinical attachment level 
2.9 
(2.9±0.7) 
3.1 
(3.5±1.3) 
2.6 
(2.6±0.7) 
0.102† 
Salivary Evaluation 
Unstimulated saliva flow 
rate (ml/min) 
0.4 
(0.4±0.29) 
0.26 
(0.28±0.18) 
0.26 
(0.35±0.29) 
0.036† 
Unstimulated saliva pH 
7.4 
(7.14±0.51) 
7.4 
(7.24±0.69) 
6.8 
(6.89±0.46) 
0.120† 
Stimulated saliva flow rate 
(ml/min) 
1.36 
(1.55±0.88) 
0.88 
(1.02±0.49) 
1.16 
(1.42±0.81) 
0.024† 
Stimulated saliva pH 
8.0 
(7.75±0.4) 
8.0 
(7.73±0.43) 
7.7 
(7.65±0.36) 
0.435† 
Values are presented as n (%) for categorical variables or median (mean±standard deviation). 
†Testing of group differences by Kruskall-Wallis test. *Testing of group differences by chi-square 
test. 
  
 Figure 12. 
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Figure 13. 
 
Figure 14. The distribution of unstimulated saliva flow rate by groups. 
comparison of RTRs, HD patients and 
 
Distribution of gingival index scores by group.
 
LKDs for unstimulated saliva flow rate.
Each node shows 
the sample average 
rank of Group. 
 
 
 
Pairwise 
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Figure 15. The distribution of stimulated saliva flow rate by groups. Pairwise comparison 
of RTRs, HD patients and LKDs for stimulated saliva flow rate. 
  
Each node shows 
the sample average 
rank of Group. 
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Figure 16. Distribution of unstimulated and stimulated saliva flow rate by patients with 
or without the feeling of a dry mouth. 
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The oral health evaluation data in RTRs receiving CsA, Tac and ERL, and LKD 
control group is given in Table 4. No significant differences were observed in oral 
hygiene habits and oral symptoms among the three groups (Table 4). No 
significant differences were found regarding visible plaque index and DMFT index 
among the studied groups (Table 4). 
Statistically significant differences were observed in bleeding on probing among 
the three RTRs groups (Table 4). Through multiple comparisons tests are observed 
differences in bleeding on probing. These differences reveal that ERL present 
median values significantly lower when compared with RTRs receiving CsA. These 
results are illustrated in the graphs of Figure 17. 
Concerning clinical attachment level, positive cases for gingival enlargement were 
excluded, and no differences were found among the three groups (Table 4). In 
addition, both unstimulated and stimulated saliva, flow rate and pH, did not differ 
among all studied groups (Table 4). 
Concerning GI and GE, no statistical analysis could be performed due to the 
reduced number of cases distributed by group. 
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Table 4. Oral hygiene habits, oral symptoms, teeth evaluation, periodontal evaluation 
and salivary evaluation of RTRs receiving CsA, Tac and ERL. 
 
CsA 
(n=29) 
Tac 
(n=36) 
ERL 
(n=23) 
p 
Oral hygiene habits 
Daily tooth brushing <2 
times per day  
8 
(33.3) 
15 
(46.9) 
5 
(26.3) 
0.302* 
Change toothbrush <4 
times per year 
12 
(41.4) 
10 
(27.8) 
11 
(50.0) 
0.405* 
Oral symptoms 
Dry mouth 14(58.3) 20(62.5) 10(55.6) 0.809* 
Bad breath 13(54.2) 18(56.3) 14(73.7) 0.366* 
Teeth evaluation 
Visible Plaque index 92(86±21) 100(92±12) 87(82±23) 0.099† 
Decayed 1 (2±4) 2 (3±4) 1 (3±3) 0.321† 
Missing 0 (1±2) 0 (1±2) 1 (5±5) 0.120† 
Filled 7 (8±7) 4 (6±6) 6 (7±5) 0.386† 
DMFT index 13 (12±7) 10 (11±7) 12(11±6) 0.812† 
Periodontal evaluation 
Bleeding on probing  
12.5 
(19.7±22.2) 
8 
(15±20.7) 
2 
(5.5±9.6) 
0.004† 
Clinical attachment level 
3.2 
(3.1±0.9) 
2.6 
(2.8±0.6) 
2.8 
(2.9±0.7) 
0.059† 
Salivary evaluation 
Unstimulated saliva flow 
rate (ml/min) 
0.48 
(0.47±0.28) 
0.40 
(0.43±0.33) 
0.34 
(0.41±0.27) 
0.550† 
Unstimulated saliva pH 
7.4 
(7.14±0.49) 
7.4 
(7.11±0.46) 
7.4 
(7.2±0.61) 
0.428† 
Stimulated saliva flow rate 
(ml/min) 
1.36 
(1.53±0.86) 
1.32 
(1.59±0.9) 
1.28 
(1.51±0.9) 
0.866† 
Stimulated saliva pH 
8.0 
(7.75±0.47) 
8.0 
(7.72±0.4) 
8.0 
(7.8±0.27) 
0.764† 
Values are presented as n (%) or median (mean ± standard deviation). 
†Testing of group differences by Kruskall-Wallis test or * chi-square test. 
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Sample 
Test Std. 
Std. 
Test Sig. 
1-Sam. Statistic Error Statistic 
1-2 15.588 6.684 -2.332 .020 
1.0 20.117 6.999 2.784 0.04 
2.0 4.529 6.228 .727 .467 
 
 
 
 
 
Figure 17. The distribution of bleeding on probing by group. 
 
3 Oral fungi characterization 
The prevalence of fungi isolated from whole saliva (stimulated) of RTR receiving 
CsA, Tac or ERL, and HD patients and LKD as group control are presented in Table 
5. The prevalence of fungi isolated from whole saliva (stimulated) in RTRs 
receiving CsA, Tac and ERL were compared to HD patients and LKD (Table 5). No 
differences were found among all studied groups (Table 5). 
Each row testes the null hypothesis that sample 1 
and Sample 2 distributions are the same. 
Asymptotic significances (2-sided tests) are 
displayed. The significance level is .05 
Each node shows 
the sample average 
rank of Group. 
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Table 5. Prevalence of fungi isolated from whole saliva (stimulated) among RTRs 
receiving CsA, Tac and ERL, HD and LKDs groups. 
 CsA Tac ERL HD LKD p 
Fungi prevalence 
(%) 
10 (37) 15 (52) 8 (36) 9 (41) 5 (38) 0.780 
Fungi 
quantification 
log CFU/ml 
2.67±0.22 2.77±0.15 2.48±0.17 2.58±0.25 2.84±0.38 0.830 
Values are presented as number (%) and as mean ± standard deviation. Testing of group 
differences by *chi-square test or #one-way ANOVA. 
 
Identification of Candida albicans and Candida krusei was possible due to the 
specific colour of the colonies, green and pink respectively) – Figures 18 and 19. 
Candida albicans was the most prevalent species identified among the studied 
groups (Figure 20). Besides C. albicans, C. krusei and C. parapsilosis were also 
detected in the studied groups (Figure 20). Although the incubation conditions 
have been specific to yeasts, molds were also found in all studied groups (Figure 
20). 
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Figure 18. Green colonies of Candida albicans. 
 
 
Figure 19. Pink colonies of Candida krusei. 
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Figure 20. Fungi isolated from whole 
 
4 Saliva analysis 
The composition of saliva
Concerning unstimulated saliva, s
in potassium levels among the three groups 
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revealed that HD patients
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Statistically significant differences were observed in urea, uric acid and creatinine 
levels among the three groups (Table 6). Through multiple comparisons tests are 
observed differences in urea, uric acid and creatinine levels. These differences 
reveal that HD patients presented median values of urea significantly higher when 
compared with RTRs and LKDs, these results are illustrated in the graphs of Figure 
22; median values of uric acid significantly higher when compared with RTRs, 
these results are illustrated in the graphs of Figure 23; median values of creatinine 
significantly higher when compared with RTRs and LKDs, these results are 
illustrated in the graphs of Figure 24. 
Statistically significant differences were observed in LDL and triglycerides among 
the three groups (Table 6). Through multiple comparisons tests are observed 
differences in LDL and triglycerides levels. These differences reveal that HD 
patients present median values of LDL significantly higher when compared with 
RTRs, these results are illustrated in the graphs of Figure 25. And, RTRs present 
median values of triglycerides significantly lower when compared with LKDs, these 
results are illustrated in the graphs of Figure 26. 
No significant differences were observed in total proteins, CRP and albumin among 
the three groups (Table 6). Statistically significant differences were observed in 
AST among the three groups (Table 6). Through multiple comparisons tests are 
observed differences in AST levels. These differences reveal that HD patients 
present median values of AST significantly higher when compared with RTRs, 
these results are illustrated in the graphs of Figure 27. Statistically significant 
differences were observed in LDH among the three groups (Table 6). Through 
multiple comparisons tests are observed differences in LDH levels. These 
differences reveal that RTRs present median values of LDH significantly lower 
when compared with LKDs, these results are illustrated in the graphs of Figures 
28. Statistically significant differences were observed in ALP among the three 
groups (Table 6). Through multiple comparisons tests are observed differences in 
ALP levels. These differences reveal that HD patients present median values of ALP 
significantly higher when compared with RTRs. Additionally, RTRs present median 
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values of ALP significantly higher when compared with LKDs, these results are 
illustrated in the graphs of Figures 29. 
Concerning stimulated saliva, statistically significant differences were observed in 
potassium levels among the three groups (Table 6). Through multiple comparisons 
tests are observed differences in potassium levels. These differences reveal that 
HD patients present median values significantly higher when compared with RTRs 
and LKDs. These results are illustrated in the graphs of Figure 30. No significant 
differences were observed in chloride, magnesium, iron, phosphate and α-amylase 
levels among the three groups (Table 6). 
Statistically significant differences were observed in IgA and s-IgA among the three 
groups (Table 6). Through multiple comparisons tests are observed differences in 
IgA and s-IgA levels. These differences reveal that HD patients present median 
values of IgA and s-IgA significantly higher when compared with RTRs. These 
results are illustrated in the graphs of Figures 31 and 32. 
Statistically significant differences were observed in IgG among the three groups 
(Table 6). HD patients present median values of IgG significantly higher when 
compared with RTRs. These results are illustrated in the graph of Figure 33. 
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Table 6. Saliva composition in RTRs, HD and LKDs groups. 
Unstimulated Saliva RTR HD LKD p 
Electrolytes 
Potassium (mmol/l) 
24.40 
(25.17±9.4) 
32.90 
(40.47±22.62) 
29.05 
(31.83±8.83) 
0.001 
Chloride (mmol/l) 
55.80 
(62.96±39.26) 
58.85 
(59.55±20.83) 
62.85 
(79.53-33.56) 
0.132 
Calcium (mg/dl) 
2.86 
(4.14±3.28) 
3.42 
(5.69-4.89) 
3.55 
(4.49-3.87) 
0.592 
Sodium (mg/dl) 
52.8 
(60.4±56.1) 
44.45 
(46.59±43.82) 
52.45 
(47.69-33.69) 
0.843 
Magnesium (mmol/l) 
0.14 
(0.2±0.2) 
0.15 
(1.98-6.16) 
0.15 
(1.61±4.6) 
0.395 
Iron (mg/L) 
0.02 
(0.09±0.21) 
0.04 
(0.16±0.24) 
0.15 
(0.16±0.14) 
0.159 
Phosphate (mg/dl) 
16.67 
(16.83±4.24) 
18.78 
(23.18±16.32) 
15.21 
(20.56±19.6) 
0.274 
Organic Part 
Urea (mg/dl) 
75.37 
(84.01±33.41) 
155.05 
(169.4±161.39) 
54.33 
(108.89-142.68) 
<0.001 
Uric acid (mg/dl) 
3.72 
(4.45±2.69) 
2.02 
(2.34±2.04) 
2.86 
(3.09±2.17) 
0.010 
Creatinine (mg/dl) 
0.1 
(0.2±0.18) 
0.82 
(1.03±0.68) 
0.1 
(0.15±0.1) 
<0.001 
Lipid Profile 
Cholesterol-LDL (U/L) 
0.25 
(1±2.78) 
0.79 
(4±6.41) 
0.3 
(3.12±6.43) 
0.008 
Triglycerides (mg/dl) 
8 
(23.22±32.81) 
23.19 
(48±56.93) 
60.01 
(60.61±26.24) 
0.009 
Proteins 
Total proteins  (mg/Ll) 
0.7 
(579.65±860.54) 
2.33 
(766.65±1209.29)
1030 
(960.87±1063.68)
0.364 
C-reactive protein 
(mg/l)  
0.03 
(28.97±68.57) 
0.02 
(0.08±0.21) 
0.03 
(0.1±0.2) 
0.081 
Albumin (mg/l) 
47.3 
(63.94±53.04) 
44.7 
(44.02±32.6) 
29.45 
(56.43±59.93) 
0.771 
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Table 6. Saliva composition in RTRs, HD and LKDs groups. 
Unstimulated Saliva RTR HD LKD p 
Aspartate 
Aminotransferase (U/l) 
32.9 
(50.02±62.8) 
74.9 
(119.55±111.74) 
28 
(50.86±54.49) 
0.003 
Lactate dehydrogenase 
(U/l) 
83 
(124.23±118.55) 
271.5 
(258.9±178.29) 
212 
(327.2±293.38) 
0.011 
Alkaline phosphatase 
(U/l) 
7.5 
(25.38-77.74) 
18.7 
(52.66-90.72) 
5.15 
(11.12-14.29) 
0.005 
Stimulated Saliva  
Electrolytes 
Potassium (mmol/l) 
20.70 
(21.64±5.13) 
27.80 
(29.90±12.49) 
21.80 
(21.78±8.87) 
<0.001 
Chloride (mmol/l) 
22.35 
(25.99±12.99) 
23.30 
(25.83±13.63) 
24.85 
(35.58±34.93) 
0.949 
Magnesium (mmol/l) 
0.06 
(0.09±0.13) 
0.09 
(0.15±0.15) 
0.08 
(0.09±0.05) 
0.139 
Iron (mg/l) 
0.01 
(0.02±0.02) 
0.02 
(0.04±0.04) 
0.01 
(0.01±0.01) 
0.067 
Phosphate (mg/dl) 
13.16 
(13.92±3.58) 
17.41 
(16.86±5.55) 
15.52 
(15.39±4.23) 
0.055 
Proteins 
α-amylase (U/l) 
129.3 
(226.45±276.25) 
92.30 
(206.42±241.64) 
107.60 
(115.66±65.18) 
0.288 
Immunoglobins  
Immunoglobulin A 
(U/l) 
0.06 
(0.08±0.07) 
0.08 
(0.12±0.09) 
0.08 
(0.08±0.04) 
0.012 
Immunoglobulin G (U/l) 0.02(0.03±0.04) 0.03(0.05±0.05) - 0.049 
Values are presented as median (mean±standar deviation). Testing of group differences by 
Kruskall-Wallis test. 
 
Figure 21. The distribution of 
comparisons of RTRs, HD and LKDs groups for potassium in unstimulated saliva
 
Figure 22. The distribution of 
comparisons of RTRs, HD and LKDs groups for 
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Figure 23. The distribution of uric acid in unstimulated saliva by group. Pairwise 
comparisons of RTRs, HD and LKDs groups for uric acid in unstimulated saliva. 
 
 
 
 
Figure 24. The distribution of creatinine in unstimulated saliva by group. Pairwise 
comparisons of RTRs, HD and LKDs groups for creatinine in unstimulated saliva. 
Each node shows 
the sample average 
rank of Group. 
Each node shows 
the sample average 
rank of Group. 
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Figure 25. The distribution of LDL in unstimulated saliva by group. Pairwise comparisons 
of RTRs, HD and LKDs groups for LDL in unstimulated saliva. 
 
 
 
 
Figure 26. The distribution of triglycerides in unstimulated saliva by group. Pairwise 
comparisons of RTRs, HD and LKDs groups for triglycerides in unstimulated saliva. 
Each node shows 
the sample average 
rank of Group. 
Each node shows 
the sample average 
rank of Group. 
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Figure 27. The distribution of AST in unstimulated saliva by group. Pairwise comparisons 
of RTRs, HD and LKDs groups for AST in unstimulated saliva. 
 
 
 
 
 
Figure 28. The distribution of LDH in unstimulated saliva by group. Pairwise 
comparisons of RTRs, HD and LKDs groups for LDH in unstimulated saliva. 
Each node shows 
the sample average 
rank of Group. 
Each node shows 
the sample average 
rank of Group. 
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Figure 29. The distribution of ALP in unstimulated saliva by group. Pairwise comparisons 
of RTRs, HD and LKDs groups for ALP in unstimulated saliva. 
 
 
 
Figure 30. The distribution potassium in stimulated saliva by group. Pairwise 
comparisons of RTRs, HD and LKDs groups for potassium in stimulated saliva. 
Each node shows 
the sample average 
rank of Group. 
Each node shows 
the sample average 
rank of Group. 
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Figure 31. The distribution of 
RTRs, HD and LKDs groups for 
 
Figure 32. The distribution of 
of RTRs, HD and LKDs groups for 
 
IgA in stimulated saliva by group. Pairwise comparisons of 
IgA in stimulated saliva.
 
s-IgA in stimulated saliva by group. Pairwise comparisons 
s-IgA in stimulated saliva.
 
 
 
 
 
 
Each node shows 
the sample average 
rank of Group. 
Each node shows 
the sample average 
rank of Group. 
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Figure 33. The distribution of immunoglobulin G in stimulated saliva by group. 
 
The composition of saliva in RTRs receiving CsA, Tac and ERL is given in Table 7. 
Concerning unstimulated saliva, statistically significant differences were observed 
in potassium levels among RTRs receiving CsA, Tac and ERL (Table 7). Through 
multiple comparisons tests are observed differences in potassium levels. These 
differences reveal that RTRs receiving Tac present median values significantly 
higher when compared with RTRs receiving CsA. These results are illustrated in 
the graphs of Figure 34. No significant differences were observed in chloride, 
calcium, sodium, magnesium and iron among the studied groups (Table 7). 
Statistically significant differences were observed in phosphate levels among RTRs 
receiving CsA, Tac and ERL (Table 7). Through multiple comparisons tests are 
observed differences in phosphate levels. These differences reveal that RTRs 
receiving CsA present median values significantly lower when compared with 
RTRs receiving Tac and ERL. These results are illustrated in the graphs of Figure 
35. 
No significant differences were observed in urea, uric acid, creatinine, LDL and 
triglycerides among the studied groups (Table 7). 
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Regarding proteins levels in unstimulated saliva, no significant differences were 
observed in total proteins, albumin, LDH and ALP among the studied groups (Table 
7). Statistically significant differences were observed in CRP levels among RTRs 
receiving CsA, Tac and ERL (Table 7). Through multiple comparisons tests are 
observed differences in CRP levels. These differences reveal that RTRs receiving 
Tac present median values significantly higher when compared with RTRs 
receiving CsA and ERL. These results are illustrated in the graphs of Figure 36. 
Statistically significant differences were observed in AST levels among RTRs 
receiving CsA, Tac and ERL (Table 7). Through multiple comparisons tests are 
observed differences in AST levels. These differences reveal that RTRs receiving 
Tac present median values significantly lower when compared with RTRs 
receiving CsA and ERL. These results are illustrated in the graphs of Figure 37.  
Concerning stimulated saliva, no significant differences were observed in 
potassium, chloride, magnesium, iron and phosphate among the studied groups 
(Table 7).No significant differences were observed in α-amylase, IgA, s-IgA and IgG 
among the studied groups (Table 7). 
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Table 7. Saliva composition of RTRs receiving CsA, Tac or ERL. 
Unstimulated Saliva CsA Tac ERL p 
Electrolytes 
Potassium (mmol/l) 21.30 
(20.57±8.65) 
26.75 
(29.45±10.86) 
24.10 
(25.31±5.62) 
0.017 
Chloride (mmol/l) 36.50 
(62.68±49.4) 
61.3 
(69.31±36.77) 
55.8 
(56.24±28.78) 
0.333 
Calcium (mg/dl) 2.66 
(4.67±4.44) 
2.72 
(3.98±2.93) 
3.09 
(3.71±1.84) 
0.654 
Sodium (mg/dl) 90.9 
(87.5±75.77) 
34.40 
(44.95±48.23) 
55.4 
(53.73±32.70) 
0.813 
Magnesium (mmol/l) 0.10 
(0.2±0.28) 
0.18 
(0.22±0.17) 
0.15 
(0.18±0.11) 
0.236 
Iron (mg/L) 0.02 
(0.16±0.32) 
0.02 
(0.09±0.15) 
0.01 
(0.02-0.03) 
0.935 
Phosphate (mg/dl) 13.84 
(14.15±2.93) 
18.90 
(18.42±3.80) 
19.43 
(18±4.63) 
0.005 
Organic Part 
Urea (mg/dl) 68.99 
(77.27±33.71) 
85.53 
(86.07±29.49) 
87.47 
(88.48±37.58) 
0.238 
Uric acid (mg/dl) 3.23 
(3.74±2.51) 
3.97 
(5.01±2.91) 
4.89 
(4.48±2.59) 
0.364 
Creatinine (mg/dl) 0.10 
(0.14±0.09) 
0.10 
(0.23±0.22) 
0.10 
(0.22±0.18) 
0.229 
Lipid Profile 
Cholesterol-LDL (U/L)  0.22 
(1.68±4.33) 
0.16 
(0.55±1.03) 
0.32 
(0.66±1.06) 
0.206 
Triglycerides (mg/dl) 8 
(25.11±35.68) 
8 
(26.83-40.66) 
8 
(17.46-17.70) 
0.986 
Proteins 
Total proteins 
(mg/Ll)  
0.68 
(0.33-3116.00) 
0.79 
(0.23-3274.00) 
0.59 
(0.02-1474.00) 
0.196 
C-reactive protein 
(mg/l)  
0.03 
(0.03±0.01) 
71.50 
(94.07±97.25) 
0.03 
(0.03±0.02) 
<0.001 
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Table 7. Saliva composition of RTRs receiving CsA, Tac or ERL. 
Stimulated Saliva CsA Tac ERL p 
Proteins 
Albumin (mg/l)  
59.58 
(74.67±60.64) 
65.85 
(64.13±44.55) 
22.86 
(44.42±44.54) 
0.377 
Aspartate Aminotransferase 
(U/l)  
59.90 
(75.34±53.90) 
0.05 
(33.56-83) 
44 
(41.50-24.14) 
<0.001 
Lactate dehydrogenase (U/l)  
172.00 
(149.56±99.58) 
64.15 
(89±79.97) 
65 
(136.26±155.99) 
0.177 
Alkaline phosphatase (U/l)  
8.50 
(45.14±130.45) 
6.90 
(22.16±45.51) 
9.35 
(10.16±5.39) 
0.554 
Electrolytes 
Potassium (mmol/l)  
20.10 
(20.88±5.04) 
20.70 
(22.16±5.65) 
21.35 
(22.00±4.82) 
0.527 
Chloride (mmol/l)  
22.30 
(24.25±13.88) 
22.75 
(27.53±11.72) 
22.25 
(26.40±13.70) 
0.418 
Calcium (mg/dl) 
3.53 
(3.48±0.65) 
3.13 
(3.45±1.33) 
2.66 
(2.63±0.69) 
 
Magnesium (mmol/l)  
0.05 
(0.12±0.19) 
0.06 
(0.09±0.08) 
0.07 
(0.08±0.04) 
0.417 
Iron (mg/l)  
0.01 
(0.02±0.03) 
0.01 
(0.02±0.02) 
0.02 
(0.02±0.01) 
0.993 
Phosphate (mg/dl)  
12.06 
(13.21±3.83) 
14.11 
(14.68±3) 
12.86 
(13.94±3.85) 
0.658 
Proteins 
α-amylase (U/l) 
148.75 
(214.80±202.72) 
173.80 
(264.90±295.11) 
98.30 
(195.43±332.15) 
0.158 
Immunoglobulins 
Immunoglobulin A  (U/l) 0.06 
(0.07±0.07) 
0.06 
(0.07±0.09) 
0.07 
(0.08±0.05) 
0.275 
Immunoglobulin G (U/l) 0.02 
(0.04±0.04) 
0.01 
(0.03±0.03) 
0.02 
(0.03±0.03) 
0.444 
Values are presented as median (mean±standard deviation). Testing of group differences by 
Kruskall-Wallis test. 
 
Figure 34. The distribution 
comparisons of CsA
 
Figure 35. The distribution of 
comparisons of CsA
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Figure 36. The distribution of 
comparisons of CsA
 
Figure 37. The distribution of 
of CsA, Tac
 
CRP in unstimulated saliva by group.
, Tac and ERL groups for CRP in unstimulated saliva.
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5 Serum biochemical parameters 
The serum biochemical parameters in RTRs, HD patients and LKDs group are given 
in Table 8. Statistically significant differences were observed in hemogram 
parameters such as hematocrit, leucocytes, eosinophils, lymphocytes and 
monocytes levels among the three groups (Table 8). Concerning general chemistry, 
statistically significant differences were observed in total cholesterol, HDL 
cholesterol, LDL cholesterol, triglycerides, glucose, urea, uric acid, creatinine, 
calcium, sodium, potassium, chloride, inorganic phosphorus, magnesium and 
transferrin levels among the three groups (Table 8). Statistically significant 
differences were observed in the levels of total proteins, albumin, ALP and 
parathormone among the three groups (Table 8). 
Table 8. Serum biochemical parameters assessed in RTRs, HD and LKDs groups. 
 RTR HD LKD P 
Hemogram 
Hemoglobin (g/dl) 
12.50 
(13±3.6) 
11.1 
(11.3±1.7) 
13.6 
(13.6±0.8) 
<0.001 
Hematocrit (%) 
38.30 
(38.9±6.3) 
31.9 
(31.8±9.1) 
40.5 
(40.6±2.2) 
<0.001 
Platelets (x109/L) 
206.00 
(211±68) 
207 
(208±44) 
218 
(218±34) 
0.862 
Leucocytes (%) 
8 
(377±1618) 
6 
(6±2) 
6 
(7±2) 
0.023 
Neutrophils (%) 
61 
(61±10) 
61 
(54±24) 
57 
(57±7) 
0.362 
Eosinophils (%) 
1.4 
(1.6±1.1) 
2.4 
(2.4±1.6) 
2.3 
(3.6±3.5) 
0.016 
Basophils (%) 
0.3 
(0.4±0.3) 
0.4 
(0.4±0.2) 
0.4 
(0.5±0.4) 
0.388 
Lymphocytes (%) 
25.9 
(26.7±9.1) 
23.0 
(21.5±10.6) 
30.6 
(31.0±6.4) 
0.023 
Monocytes (%) 
9 
(9.3±2.8) 
7.1 
(6.7±3.9) 
7.4 
(7.7±1.7) 
0.004 
General Chemistry 
Total cholesterol (mg/dl) 
203 
(208±50) 
160 
(168±29) 
200 
(204±28) 
0.003 
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 RTR HD LKD P 
HDL cholesterol (mg/dl) 
52 
(56±18) 
37 
(42±14) 
55 
(57±12) 
0.003 
LDL cholesterol (mg/dl) 
131 
(130±33) 
96 
(107±38) 
130 
(128±23) 
0.021 
Triglycerides (mg/dl) 
138 
(151±72) 
200 
(224±135) 
83 
(101±47) 
0.001 
Glucose (mg/dl) 
82 
(81±16) 
96 
(113±67) 
76 
(72±8) 
0.002 
Urea (mg/dL) 
61 
(66±26) 
111 
(107±77) 
36 
(35±11) 
<0.001 
Uric acid (mg/dl) 
6.8 
(10.2±14.7) 
8.2 
(17.3±18.1) 
4.1 
(8.0±14.5) 
<0.001 
Creatinine  (mg/dl) 
1.55 
(1.67±0.92) 
8.75 
(10.28±7.23) 
0.80 
(0.78±0.20) 
<0.001 
Calcium (mEq/L) 
5.0 
(5.0±0.4) 
5.1 
(6.3±2.3) 
4.7 
(4.6±0.7) 
0.010 
Sodium (mEq/L) 
140 
(140±2) 
136 
(136±2) 
138 
(136±8) 
<0.001 
Potassium (mEq/L) 
4.2 
(4.2±0.5) 
4.7 
(4.8±0.7) 
4.0 
(4.0±0.3) 
0.001 
Chloride (mEq/L) 
106 
(106±3) 
98 
(99±5) 
103 
(103±2) 
<0.001 
Inorganic Phosphorus 
(mg/dl) 
3.0 
(4.9±7.7) 
4.8 
(17.3±26.2) 
3.6 
(5.3±6.4) 
<0.001 
Iron (ug/dl) 
82 
(83±30) 
59 
(73±40) 
73 
(86±28) 
0.263 
Magnesium (mmol/l) 
1.42 
(1.42±0.20) 
1.61 
(1.74±0.45) 
1.66 
(1.68±0.10) 
<0.001 
Transferrin (mg/dl) 
204 
(212±44) 
218 
(225±47) 
282 
(267±27) 
0.006 
Ferritin (ng/ml) 
127 
(234±219) 
431 
(449±352) 
80 
(125±118) 
0.066 
Proteins 
Total proteins (mg/L) 
69.7 
(69.1±4.8) 
71.2 
(67.8±9.9) 
73.1 
(75.3±9.2) 
0.008 
C-reactive protein (mg/L) 
2 
(7±15) 
4 
(18±32) 
2 
(9±14) 
0.161 
Albumin (mg/L) 41.4 41.0 44.3 0.019 
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 RTR HD LKD P 
(41.6±3.2) (38.8±6.8) (44.2±2.5) 
Aspartate aminotransferase 
(U/L) 
20 
(22±10) 
20 
(20±7) 
18 
(19±5) 
0.687 
Alanine aminotransferase 
(U/L) 
17 
(23±24) 
17 
(19±7) 
13 
(15±5) 
0.223 
Alkaline phosphatase (U/L) 
72 
(75±30) 
115 
(120±57) 
51 
(55±10) 
0.001 
Immunoglobulin A (mg/dl) 
185 
(240±190) 
244 
(298±180) 
141 
(141±123) 
0.332 
Immunoglobulin G (mg/dl) 
926 
(940±318) 
987 
(1052±234) 
1645 
(1645±686) 
0.123 
Immunoglobulin M(mg/dl) 
95 
(105±54) 
73 
(89±38) 
155 
(155±85) 
0.503 
Immunoglobulin E (mg/dl) 
29 
(161±295) 
- 
151 
(151± -) 
0.380 
Complement 
Complement  C3c (mg/dl) 
120 
(122±31) 
147 
(127±30) 
128 
(128±16) 
0.710 
Complement C4 (mg/dl) 
23 
(27±12) 
34 
(35±11) 
22 
(22±1) 
0.132 
Endocrinology 
Vitamin D (pg/ml) 
18 
(198±1048) 
9 
(12±8) 
- 0.054 
Parathormone(pg/) 
100.9 
(125.4±98.3) 
401.8 
(455.3±333.6) 
50.4 
(55.4±10.4) 
<0.001 
Values are presented as median (mean±standard deviation). Testing of group differences by Kruskall-
Wallis test. 
 
The serum biochemical parameters in RTRs receiving CsA, Tac and ERL group are 
given in Table 9. Statistically significant differences were observed in hemogram 
parameters such as leucocytes and monocytes levels among the three groups 
(Table 9). Concerning proteins, statistically significant differences were observed 
in the levels of total proteins and CRP (Table 9). 
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Table 9. Serum biochemical parameters assessed in RTRs receiving CsA, Tac or ERL. 
 CsA Tac ERL P 
Hemogram 
Hemoglobin (g/dl) 
12.8 
(13.8±5.8) 
12.1 
(12.5±1.6) 
12.6 
(12.9±1.8) 
0.435 
Hematocrit (%) 
38.3 
(38.1±8.3) 
37.60 
(38.4±4.8) 
41.3 
(41.1±4.8) 
0.133 
Platelets (x109/L) 
196 
(194±58) 
207 
(208±51) 
226 
(241±97) 
0.162 
Leucocytes (%) 
7 
(7±2) 
8. 
(375±1534) 
9 
(899±2571) 
0.043 
Neutrophils (%) 
61 
(62±10) 
62 
(62±9) 
56 
(56±10) 
0.076 
Eosinophils (%) 
1.3 
(1.5±0.9) 
1.4 
(1.5±1.3) 
1.7 
(1.9±1.1) 
0.108 
Basophils (%) 
0.3 
(0.4±0.3) 
0.3 
(0.3±0.2) 
0.3 
(0.3±0.3) 
0.962 
Lymphocytes (%) 
25.3 
(26.5±9.1) 
24.6 
(24.6±9.1) 
29.6 
(30.6±8.4) 
0.090 
Monocytes (%) 
8.9 
(9.2±3.1) 
8.1 
(8.6±2.6) 
10.2 
(10.6±2.3) 
0.017 
General Chemistry 
Total cholesterol (mg/dl) 
230 
(225±53) 
198 
(201±47) 
198 
(195±49) 
0.115 
HDL cholesterol (mg/dl) 
54 
(54±15) 
50 
(57±21) 
59 
(58±15) 
0.600 
LDL cholesterol (mg/dl) 
147 
(143±37) 
127 
(124±30) 
116 
(118±20) 
0.168 
Triglycerides (mg/dl) 
135 
(141±48) 
131 
(145±76) 
181 
(185±93) 
0.153 
Glucose (mg/dl) 
86 
(82±18) 
85 
(82±15) 
77 
(77±14) 
0.167 
Urea (mg/dL) 
62 
(69±32) 
58 
(62±21) 
69 
(68±24) 
0.395 
Uric acid (mg/dl) 
7.2 
(14.0±21.6) 
6.6 
(8.3±9.9) 
6.9 
(8.3±6.9) 
0.484 
Creatinine (mg/dl) 
1.38 
(1.57±0.61) 
1.49 
(1.66±1.17) 
1.6 
(1.83±0.86) 
0.566 
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 CsA Tac ERL P 
Calcium (mEq/L) 
4.9 
(5.0±0.2) 
5.0 
(5.0±0.6) 
5.2 
(5.1±0.3) 
0.168 
Potassium (mEq/L) 
4.1 
(4.2±0.3) 
4.2 
(4.3±0.4) 
3.9 
(4.1±0.8) 
0.600 
Sodium (mEq/L) 
139 
(139±2) 
140 
(139±2) 
141 
(141±3) 
0.115 
Chloride (mEq/L) 
107 
(106±3) 
106 
(106±3) 
106 
(106±3) 
0.638 
Inorganic Phosphorus 
(mg/dl) 
3.1 
(6.0±9.3) 
2.8 
(4.2±7.1) 
3.0 
(4.5±6.1) 
0.153 
Iron (ug/dl) 
79 
(85±31) 
85 
(85±28) 
72 
(76±33) 
0.167 
Magnesium (mmol/l)  
1.46 
(1.46±0.16) 
1.29 
(1.33±0.20) 
1.53 
(1.54±0.20) 
0.395 
Transferrin (mg/dl)  
209 
(214±44) 
200 
(212±49) 
222 
(210±38) 
0.786 
Ferritin (ng/ml) 
192 
(233±168) 
103 
(215±218) 
118 
(272±297) 
0.543 
Iron /transferrin x 70.9 
(%) 
26 
(29±14) 
28 
(30±12) 
25 
(26±10) 
0.762 
Proteins 
Total proteins (mg/L) 
66.5 
(68.1±5.1) 
69.5 
(68.5±4.7) 
71.6 
(72.0±3.6) 
0.013 
C-reactive protein (mg/L) 
2 
(3±3) 
2 
(5±11) 
6 
(15±25) 
0.011 
Albumin (mg/L) 
41.1 
(41.0±2.7) 
42.9 
(42.3±3.9) 
41.3 
(41.3±2.3) 
0.064 
Aspartate 
aminotransferase (U/L) 
22 
(22±6) 
18 
(21±14) 
21 
(22±6) 
0.195 
Alanine aminotransferase 
(U/L) 
17 
(20±10) 
15 
(28±35) 
19 
(18±6) 
0.791 
Alkaline phosphatase 
(U/L) 
75 
(78±27) 
67 
(72±32) 
71 
(78±33) 
0.601 
Immunogloblins 
Immunoglobulin A 
(mg/dl) 
174 
(185±86) 
184 
(228±114) 
242 
(343±354) 
0.553 
Immunoglobulin G 876 931 1035 0.851 
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 CsA Tac ERL P 
(mg/dl) (902±270) (939±317) (992±407) 
Immunoglobulin M 
(mg/dl) 
113 
(100±54) 
94 
(109±61) 
104 
(101±45) 
0.846 
Immunoglobulin E 
(mg/dl) 
8 
(8±1) 
73 
(263±367) 
- 0.083 
Complement 
C3c Complement (mg/dl) 
107 
(114±21) 
118 
(116±31) 
136 
(143±34) 
0.121 
C4 Complement  
(mg/dl) 
22 
(21±5) 
24 
(26±11) 
40 
(35±13) 
0.128 
Endocrinology 
Vitamin D (pg/ml) 
19 
(573±1843) 
17 
(19±9) 
15 
(17±7) 
0.755 
Parathormone(pg/ml) 
91.5 
(99.0±45.7) 
100.5 
(135.2±118.7) 
122.4 
(148.5±111.5) 
0.266 
Values are presented as median (mean±standar deviation). Testing of group differences by 
Kruskall-Wallis test. 
 
The ratio saliva/serum of biochemical parameters in RTRs, HD and LKDs groups, is 
given in Table 10. 
Statistically significant differences were observed in potassium ratio among RTRs, 
HD and LKDs groups (Table 10). Through multiple comparisons tests are observed 
differences in potassium ratio. These differences reveal that RTRs present median 
values significantly lower when compared with LKDs group. These results are 
illustrated in the graphs of Figure 38. No significant differences were observed in 
ratio saliva/serum of chloride, calcium, sodium, magnesium, iron and phosphate 
among the studied groups (Table 10). 
No significant differences were observed in urea ratio among the studied groups 
(Table 10). Statistically significant differences were observed in uric acid ratio 
among RTRs, HD and LKDs groups (Table 10). Through multiple comparisons tests 
are observed differences in uric acid ratio. These differences reveal that RTRs 
STUDY OF ORAL HEALTH STATUS IN RENAL TRANSPLANT RECIPIENTS 
Results 
 
 
87 
present median values significantly lower when compared with RTRs and LKDs 
group. These results are illustrated in the graphs of Figure 39. 
Statistically significant differences were observed in LDL ratio among RTRs, HD 
and LKDs groups (Table 10). Through multiple comparisons tests are observed 
differences in LDL ratio. These differences reveal that HD patients present median 
values significantly higher when compared with RTRs group. These results are 
illustrated in the graphs of Figure 40. 
Statistically significant differences were observed in creatinine ratio among RTRs, 
HD and LKDs groups (Table 10). Through multiple comparisons tests are observed 
differences in creatinine ratio. These differences reveal that RTRs present median 
values significantly lower when compared with LKDs group. These results are 
illustrated in the graphs of Figure 41. 
No significant differences were observed in ratio saliva/serum of triglycerides, 
total proteins, CRP, albumin and ALP among the studied groups (Table 10). 
Statistically significant differences were observed in AST ratio among RTRs, HD 
and LKDs groups (Table 10). Through multiple comparisons tests are observed 
differences in AST ratio. These differences reveal that HD patients present median 
values significantly higher when compared with RTRs group. These results are 
illustrated in the graphs of Figure 42. 
No significant differences were observed in IgA ratio among the studied groups 
(Table 10). 
 
Table 10. Ratio of biochemical parameters in saliva and blood of RTRs, HD and LKDs 
groups. 
Ratio saliva/blood RTR HD LKD p 
Electrolytes 
Potassium 
5.72 
(5.94±2.36) 
6.58 
(9.32±7.40) 
7.71 
(8.02±2.45) 
0.006 
Chloride 
0.50 
(0.61±0.38) 
0.53 
(0.58±0.23) 
0.63 
(0.78±0.32) 
0.119 
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Ratio saliva/blood RTR HD LKD p 
Calcium 
0.56 
(0.83±0.69) 
0.61 
(1.05±1.14) 
0.74 
(1.01±0.82) 
0.430 
Sodium 
0.41 
(0.46±0.40) 
0.47 
(0.36±0.27) 
0.37 
(0.35±0.24) 
0.893 
Magnesium 
0.10 
(0.14±0.16) 
0.27 
(2.14±5.08) 
0.10 
(1.01±2.91) 
0.444 
Iron 
0.003 
(0.0003±0.0002) 
0.0027 
(0.0047±0.0064) 
0.0011 
(0.0011±???) 
0.837 
Phosphate 
5.44 
(5.84±2.26) 
4.56 
(6.31±4.51) 
3.98 
(6.77±8.27) 
0.232 
Organic Part 
Urea 
1.21 
(2.91±12.13) 
1.52 
(38.76±78.10) 
1.69 
(3.51±4.5) 
0.166 
Uric acid 
0.62 
(0.65±0.39) 
0.07 
(0.2±0.3) 
0.62 
(0.69±0.57) 
0.010 
Creatinine 
0.08 
(0.13±0.12) 
0.10 
(0.12±0.11) 
0.17 
(0.23±0.16) 
0.024 
Lipid Profile 
Cholesterol-LDL 
0.00 
(0.01±0.01) 
0.01 
(0.04±0.07) 
0.00 
(0.03±0.06) 
0.009 
Triglycerides 
0.07 
(0.19±0.29) 
0.09 
(0.35±0.47) 
0.75 
(0.96±0.89) 
0.056 
Proteins 
Total proteins 
0.01 
(8.38±12.82) 
8.63 
(16.05±19.20) 
14.09 
(13.05±14.27) 
0.231 
C-reactive protein 
0.02 
(44.17±184.43) 
0.01 
(0.02±0.02) 
0.01 
(0.07±0.12) 
0.324 
Albumin 
0.95 
(1.46±1.30) 
1.34 
(1.39±0.78) 
0.64 
(1.28±1.41) 
0.839 
Aspartate 
Aminotransferase 
2.08 
(2.78±3.92) 
3.7 
(9.24±10.48) 
1.56 
(2.63±2.77) 
0.026 
Alkaline phosphatase 
0.11 
(0.46±1.25) 
0.34 
(1.34±2.99) 
0.10 
(0.21±0.28) 
0.311 
Immunogloblins 
Immunoglobulin A 
0.0003 
(0.003±0.002) 
0.006 
(0.007±0.005) 
0.0011 
(0.0011±0.001) 
0.060 
Values are presented as median (mean±standard deviation). Testing of group differences by Kruskall-
Wallis test. 
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Figure 38. The distribution of potassium ratio saliva/serum of by group. Pairwise 
comparisons of RTR, HD and LKD groups for potassium ratio saliva/serum. 
 
 
 
 
 
Figure 39. The distribution of uric acid ratio saliva/serum by group. Pairwise 
comparisons of RTR, HD and LKD groups for uric acid ratio saliva/serum. 
Each node 
shows the 
sample 
average 
rank of 
Group. 
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Figure 40. The distribution of LDL ratio
RTR, HD
 
Figure 41. The distribution of creatinine ratio saliva/serum by 
comparisons of RTR
 
 
 saliva/serum by group. Pairwise comparisons of 
 and LKD groups for LDL ratio saliva/serum.
 
group.
, HD and LKD groups for creatinine ratio saliva/serum
Each node 
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average 
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average 
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Group. 
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Figure 42. The distribution of 
RTR, HD
 
The ratio saliva/serum of biochemical parameters 
ERL is given in Table 11. 
Statistically significant differences were observed in 
receiving CsA, Tac and ERL groups
are observed differences in potassium ratio. These differences reveal that RTRs 
receiving Tac present median values significantly 
RTRs receiving CsA. These results are illustrated in the graphs of 
significant differences were observed in 
sodium, magnesium, iron and phosphate 
No significant differences were observed in 
cholesterol LDL and triglycerides
Concerning proteins, no significant differences were observed in 
ratio among the studied
were observed in CRP ratio
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 among RTRs 
Figure 43. No 
Table 11). 
1). 
total proteins 
 (Table 11). 
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Through multiple comparisons tests are observed differences in CRP ratio. These 
differences reveal differences between the three groups.  These results are 
illustrated in the graphs of Figure 44. 
Statistically significant differences were observed in AST ratio among RTRs 
receiving CsA, Tac and ERL (Table 11). Through multiple comparisons tests are 
observed differences in AST ratio. These differences reveal that RTRs receiving Tac 
present median values significantly lower when compared with RTRs receiving 
CsA and ERL. These results are illustrated in the graphs of Figure 45. 
No statistically significant differences were observed in IgA ratio and IgG ratio 
among RTRs receiving CsA, Tac and ERL (Table 11). 
Table 11. Ratio of biochemical parameters in saliva and blood of RTRs receiving CsA, 
Tac and ERL. 
Ratio saliva/blood CsA Tac ERL p 
Electrolytes 
Potassium 
4.67 
(4.88±2.10) 
6.37 
(6.92±2.74) 
5.51 
(6.0±1.37) 
0.022 
Chloride 
0.34 
(0.59±0.48) 
0.57 
(0.65±0.35) 
0.5 
(0.56±0.28) 
0.333 
Calcium 
0.52 
(0.96±0.94) 
0.56 
(0.80±0.59) 
0.59 
(0.69±0.37) 
0.908 
Sodium 
0.66 
(0.63±0.54) 
0.24 
(0.32±0.35) 
0.48 
(0.49±0.14) 
0.381 
Magnesium 
0.07 
(0.14±0.21) 
0.13 
(0.17±0.14) 
0.10 
(0.11±0.06) 
0.156 
Iron 
0.0002 
(0.0023±0.0043) 
0.0002 
(0.0011±0.0020) 
0.0003 
(0.0005±0.0005) 
0.837 
Phosphate 
4.99 
(5.35±2.66) 
5.51 
(6.41±2.26) 
5.70 
(5.79±1.74) 
0.418 
Organic Part 
Urea 
1.18 
(5.98±21.20) 
1.4 
(1.48±0.57) 
1.21 
(1.34±0.55) 
0.348 
Uric acid 
0.45 
(0.53±0.41) 
0.64 
(0.75±0.40) 
0.67 
(0.63±0.33) 0.164 
Creatinine 
0.08 
(0.1±0.07) 
0.1 
(0.15±0.14) 
0.08 
(0.15±0.13) 
0.660 
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Ratio saliva/blood CsA Tac ERL p 
Lipid Profile 
Cholesterol-LDL 
0.00 
(0.01±0.02) 
0.00 
(0.00±0.01) 
0.00 
(0.01±0.02) 
0.140 
Triglycerides 
0.07 
(0.23±0.33) 
0.08 
(0.22±0.32) 
0.07 
(0.11±0.17) 
0.622 
Proteins 
Total proteins 
0.01 
(7.39±13.22) 
0.01 
(11.71±14.92) 
0.01 
(5.1±7.85) 
0.099 
C-reactive protein 
0.03 
(0.04±0.04) 
32.73 
(159.62±342.91) 
0.01 
(0.01±0.01) 
<0.001 
Albumin 
1.37 
(1.84±1.52) 
1.47 
(1.49±0.97) 
0.38 
(0.45±0.21) 
0.051 
Aspartate 
Aminotransferase 
2.29 
(3.57±2.76) 
0.00 
(2.27±5.45) 
2.39 
(2.36±0.96) 
0.001 
Alkaline phosphatase 
0.13 
(0.7±1.79) 
0.1 
(0.49±1.13) 
0.11 
(0.15±0.10) 
0.914 
Immunoglobulins 
Immunoglobulin A 
0.0003 
(0.0004±0.0003) 
0.0002 
(0.0003±0.0001) 
0.0003 
(0.0003±0.0002) 
0.430 
Immunoglobulin G 
0.000 
(0.0000±0.0000) 
0.000 
(0.0000±0.0000) 
0.0003 
(0.0005±0.0005) 
0.158 
Values are presented as median (mean±standard deviation). Testing of group differences by Kruskall-
Wallis test. 
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Figure 43. The distribution of potassium ratio saliva/serum by group.
comparisons of CsA
 
Figure 44. The distribution of 
CsA, Tac
 
 
 
, Tac and ERL groups for potassium ratio saliva/serum
 
CRP ratio saliva/serum by group. Pairwise comparisons of 
 and ERL groups for CRP ratio saliva/serum.
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Figure 45. The distribution of ratio saliva/serum of AST by group. Pairwise comparisons 
of CsA, Tac and ERL groups for AST ratio saliva/serum. 
 
Each node 
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sample 
average 
rank of 
Group. 
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Chapter IV – Discussion 
 
 
 
The main goals of the present study were to evaluate the differences in the oral 
health status of RTRs receiving CsA, Tac or ERL, and compare it with patients on 
hemodialysis (pre-transplant) and healthy controls (living kidney donor), evaluate 
saliva composition and compare it with serum biochemical parameters. 
 
1 Oral health status 
1.1 Periodontal inflammation 
In the present study, the RTRs receiving ERL presented a lower BOP score in 
comparison to RTRs receiving CsA and RTRs receiving Tac. Bleeding on probing is 
universally accepted as a sign of periodontal inflammation that enables the 
detection of hidden-from-view periodontal inflammation. [134] According to Lindhe 
and co-workers [86], BOP percentages reflect a summary of the patient's: 1) ability 
to perform proper plaque control;  2) host response to the bacterial challenge and 
3) compliance. The percentage of sites with BOP represents an objective 
inflammatory parameter, which is used to evaluate the presence of periodontal 
disease and the risk of disease progression. [86] In addition, Ness and co-workers 
reported that BOP reflects decreased collagen density, increased blood vessel 
density and fragility and a reduction of epithelial thickness and integrity. [135] Thin, 
fragile or even discontinuous pocket epithelium, may serve as an entrance for oral 
bacteria into the systemic circulation. [135] Furthermore, BOP is characterized by a 
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dense infiltration of inflammatory cells. [86] These inflammatory cells, which have a 
key role in the pathogenesis of periodontitis, also may play a role in eliciting a 
systemic inflammatory response or cross-reactivity. [135] Thus, BOP reflects 
histological, clinical and bacteriological alterations associated with periodontal 
disease. [136] 
Previous data have shown that CNIs may induce angiogenesis by the production of 
cytokines whereas mTOR inhibitors may prevent replication of cancer cells and 
tumor angiogenesis. [137-139] Angiogenesis contributes to inflammation. New blood 
vessels may contribute to maintain the chronic inflammatory state by transporting 
inflammatory cells to the site of inflammation and by supplying nutrients and 
oxygen to the proliferating inflamed tissue. [140] In these conditions, the host 
inflammatory response in periodontitis leads to soft- and hard-tissue destruction. 
[141] Therefore, we can hypothesize that RTRs receiving ERL may be more 
protected for the development of periodontal disease in comparison to RTRs 
receiving CsA and RTRs receiving Tac, due to the distinct effects of the two 
immunossupressors in angiogenesis. 
If we compare our results with those of other studies that evaluated oral health 
status in similar populations, our BOP scores may seem low. However, one should 
mention that our results of BOP scores are presented as median (min-max) 
because the values did not follow a normal distribution.  When we present our 
results of BOP scores as mean±standard deviation, the values for the CsA, Tac, ERL 
and LKD groups were 20±22, 15±21, 6±10 and 10±10, respectively, which are 
similar to those of other studies. [131, 142] 
Renal transplant recipients receiving ERL were older than those receiving Tac. 
This finding is in agreement with previous observations and is related with the fact 
that Tac is the CNI used in our and other transplant units in RTRs younger than 45 
years, whereas in RTRs older than 45 cyclosporine A is the CNI used. [59, 143] 
Because it is known that the process of ageing may contribute to higher severity of 
periodontal disease, the finding that RTRs receiving ERL were older and presented 
less periodontal inflammation further reinforces the view that ERL may be 
endowed with protective effects on periodontal disease. 
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The time after transplant was also higher in RTRs receiving ERL than in those 
receiving CsA and RTRs receiving Tac. This is an expected finding mainly because 
CsA and Tac are a first step immunossupressive therapy used in the early post-
transplant phase whereas ERL is as second step immunossupressor used in RTRs 
switched from CNIs due to chronic CNI-related nephrotoxicity. 
Previous data showed that smoking is a risk factor for periodontal disease. In 
addition, in smokers the signs and symptoms of both gingivitis and chronic 
periodontitis, mainly gingival redness and BOP, are masked by the dampening 
inflammation seen in smokers when compared to non-smokers. [86] In the present 
study no differences were observed regarding smoking habits, both past and 
current among the three groups. Hence, we can conclude that the lower BOP scores 
in RTRs receiving ERL were not affected by smoking as confounder. 
Bacterial colonization and growth on supra- and sub-gingival tooth surfaces causes 
chronic inflammation in periodontal tissues. [144] Periodontitis is an asymptomatic 
infection that causes local impairment during its lengthened progression, but it 
may also be associated with increased risk for non-oral infections as well as to pro-
inflammatory host responses linked to systemic diseases, namely cardiovascular 
diseases. [144] Therefore, our results suggest that adequate pre- and post-transplant 
oral health care may be particularly recommended for RTRs receiving CsA and for 
those receiving Tac in order to prevent these related co-morbidities. 
 
1.2 Salivary flow rate 
We found that unstimulated and stimulated saliva flow rates were significantly 
lower in HD group than in RTRs group. Given that unstimulated saliva is related to 
lubricating and antimicrobial functions and stimulated saliva flow rate is related 
with oral clearance, our results suggest that HD patients could have a source for 
active infection in oral tissues. 
Human saliva lubricates the oral tissues and make possible oral functions such as 
speaking, eating, and swallowing, but also protects teeth and oral mucosal surfaces 
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in different ways. [145] The lubricating and antimicrobial functions of saliva are 
maintained mainly by unstimulated saliva. [145] Stimulated saliva provides a 
flushing effect and contributes to the clearance of the residues present in the 
mouth such as non-adherent bacteria, cellular and food debris and noxious agents. 
[145, 146] If changes in oral health status cause a reduction in salivary flow rate, there 
would be a drastic alteration in the level of oral cleaning. [146] Our results suggest 
that HD patients had less oral clearance than RTRs or LKDs, favoring the 
availability of sugars to the biofilm microorganisms. Therefore, adequate oral 
health care may be particularly recommended for HD patients in order to prevent 
infectious foci, because oral pathologies or infections could jeopardize the 
opportunity to receive a successful kidney transplant. 
It has been suggested that restriction of fluid intake is the most important reason 
for a reduction in saliva flow rate in HD patients. [147-149] Some authors also 
attribute this finding to a direct salivary gland involvement. [147, 150] 
Probably the most important caries-preventive functions of saliva are the flushing 
and neutralizing effects, commonly referred to as "salivary clearance" or "oral 
clearance capacity". [32, 145]  Although, in the present study HD patients had less oral 
clearance capacity than RTRs or LKDs, no differences were found in the number of 
decayed teeth among the three groups. Our findings agree with those of Bayraktar 
and co-workers. [147]  
In our study, visual plaque index revealed an unsatisfactory level of oral hygiene 
among RTRs and HD groups. In literature, previous authors have reported that 
many patients receiving renal dialysis are victims of oral neglect. [151, 152] Renal 
dialysis is time consuming and often individuals do not spend much time taking 
care of them and may ignore other potential problems. [151, 152] Therefore, 
comprehensive and periodic oral hygiene instructions are recommended to 
improve oral self-care behaviors and prevent future dental disease and disease 
progression. [151] Furthermore, opportunistic focal infections may develop at the 
site of the new transplant if bacteria-inducing dental treatment is required soon 
after transplantation. [151, 153] 
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In literature, the oral health of HD patients when compared with the general 
population is reported being worse in terms of caries, gingivitis, periodontitis, 
plaque buildup and general oral health status. [14, 187-190] 
However, in several studies a very low and non-significant correlation was 
obtained, namely for periodontal parameters. [146, 188, 190, 191] Our results did not 
show differences in terms of caries, gingivitis and periodontitis among HD patients, 
RTRs and healthy controls, LKDs. 
 
2 Oral fungi characterization 
In our study RTRs, HD patients and LKDs presented asymptomatic colonization of 
fungi in saliva. As expected, Candida albicans was the most frequent Candida 
species identified. Interestingly, non-albicans Candida strains were also identified 
namely molds. Given that Candida albicans is the most common opportunistic 
infection agent in the oral cavity, adequate oral health care may be particularly 
recommended to RTRs, due their immunosssupressive state, in order to prevent 
systemic candidiasis. 
Although certain Candida species are considered to be commensal organisms 
within the oral cavity, these fungi are also the source of Candida species that cause 
oral candidiasis and are a potential source to systemic candidiasis. [154, 155] 
The prevalence of oral fungi in the present study was similar to the results 
obtained for the general population, namely 34%. [155] 
Patients on hemodialysis are much more likely to die of infectious diseases in 
comparison to general population due to the higher frequency of infections and 
also due to the greater severity of infectious in these patients. [4] Although this 
phenomenon is partly explained by the fact that healthier HD patients are selected 
for transplantation, there is nevertheless a real susceptibility to infections in  HD 
patients, the etiology of which is multifactorial and includes a state of acquired 
immunodeficiency, immunocompromise and increased risk of exposure to 
pathogenic microorganisms. [4] 
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Renal transplant recipients have increased risk for opportunistic infections that 
could lead to graft failure. [4] Oral Candida carriage and infection have been 
reported to be associated with a greater risk for systemic infection in transplant 
recipients. [110] Prevention of fungal colonization and control of local infection may 
be of critical importance in avoiding systemic candidiasis. [156] 
In our study no differences were found when we compared the prevalence and 
quantity of fungi identified in saliva among the studied groups. Similar results 
were reported by Castillo and co-workers. [14] Nevertheless, the fungi colonization 
in RTRs and HD groups is relevant in what concerns, for example, the 
immunocompromise condition of these two groups. 
Although Candida albicans is the most frequent Candida species in the oral cavity, 
non-albicans Candida strains play an ever-increasing role as colonization agents. 
[156] In our results this is enhanced because all groups presented molds, even 
though incubation conditions have been specific to yeasts. 
 
3 Characterization of saliva composition and its relation with serum 
3.1 Electrolytes 
Potassium 
In the present study HD patients had higher levels of potassium than RTRs or LKDs 
groups, both in serum and saliva. Furthermore, when comparing HD patients with 
healthy controls, no differences were found in potassium´s ratio. So, our results 
suggest that saliva composition in HD patients is influenced by phosphate´s 
concentration in serum. 
Potassium is one of the most abundant ions in the body and is critical for many cell 
functions. [157] The kidneys regulate potassium excretion [157]. In individuals with 
CKD, the elimination incapacity of potassium leads to serum concentration rising, 
hyperkalemia. [158] Hyperkalemia is often asymptomatic and the first 
STUDY OF ORAL HEALTH STATUS IN RENAL TRANSPLANT RECIPIENTS 
Discussion 
 
 
103 
manifestations are: cardiac arrhythmias and muscle paralysis, both life-
threatening. [4] 
In the oral cavity, the main role of potassium is in saliva´s secretion. [159] The 
concentration of potassium in saliva rises at low rates of salivary secretion. [160, 161] 
The salivary glands’ secretion system can actively excrete potassium into the oral 
cavity. [158] The secretion of potassium in the saliva occurs in two phases. In the 
first, a transient high rate of potassium secretion occurs when the previously 
inactive gland is activated by nerve stimulation. Most of the potassium secreted in 
this phase comes from the intracellular potassium of the gland. In the second phase 
the output of potassium in the saliva is lower and is derived from serum through 
the intracellular pool. [159, 160] 
Given that potassium levels in saliva rise at low rates of salivary secretion and part 
of the output of potassium in saliva derives from serum, our results suggest that 
HD patients had higher levels of potassium in saliva probably due to the lower flow 
rate of salivary secretion and due to the potassium derived from serum. 
Another interesting finding was that the higher levels of salivary potassium in HD 
patients reflected the higher levels of serum potassium when compared with 
healthy controls. However, this was not found between RTRs and LKDs. 
In our study, when we compared RTRs receiving CsA, Tac and ERL, salivary 
potassium levels were higher in RTRs receiving Tac than RTRs receiving CsA. In 
addition, when we compared serum potassium levels, the results were similar. 
This is shown by the differences in potassium´s ratio between the two groups. This 
finding adds to our study extra information that allow us to hypothesize that 
salivary glands activity has determined the higher levels of potassium in RTRs 
receiving Tac, and not serum. 
Phosphate 
In the present study salivary phosphate was significantly lower in RTRs receiving 
CsA than in RTRs receiving Tac and ERL. Given that phosphate in saliva is related 
with dental structure maintenance, our results suggest that RTRs receiving Tac 
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and ERL patients are endowed with better conditions to maintain the dental 
structure in comparison to RTRs receiving CsA. 
In our study phosphate´s concentration in saliva was influenced by its 
concentration in serum for all the studied groups. 
High serum phosphate levels are common in patients treated with dialysis. [162] 
Phosphate retention and hyperphosphatemia contribute to vascular and soft 
tissues calcification and consequently to the high morbidity and mortality in HD 
patients. [162-165] Salivary fluid contains electrolytes including phosphate. [163]  In 
our study when comparing HD patients with healthy controls, no differences were 
found in phosphate´s ratio even though HD patients presented higher serum 
phosphate concentrations than LKDs and RTRs. So, our results suggest that saliva 
composition was influenced by phosphate´s concentration in serum. 
Recently,  Savica and co-workers [163] suggested that the level of salivary phosphate 
could be used as a marker for the initiation of hyperphosphatemia treatment in 
chronic kidney disease [163]. 
From our results we can hypothesize that salivary phosphate can be considered a 
marker for phosphate´s variations in serum. 
In our study when we compared RTRs receiving CsA, Tac and ERL, salivary 
phosphate was significantly lower in RTRs receiving CsA. 
Phosphate concentration in saliva depends on salivary pH and varies in accordance 
with the salivary flow. [163] The most important biological function of this ion is to 
maintain the dental structure. Another function is its buffer capacity, relevant only 
in unstimulated saliva. [146] So, our results suggest that RTRs receiving Tac and ERL 
had higher phosphate levels in saliva and consequently were endowed with better 
conditions to maintain the dental structure than RTRs receiving CsA. 
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3.2 Organic part 
Urea 
In the present study HD group had higher levels of salivary urea than RTRs or 
LKDs group. Interestingly, the levels of urea in saliva reflected urea serum levels 
among the three groups. 
Urea is formed in the liver as a major end product of the metabolism of nitrogen-
containing substances and is excreted by kidneys. [166] Measurement of urea 
nitrogen in blood is valuable for diagnosing renal diseases, particularly those 
associated with a reduction in GFR. [167] 
The concentration of urea in saliva is described by Akai and co-workers [167] to 
reflect urea levels in serum. [167] Our results confirm this finding. No differences 
were found in urea ratio between HD patients and healthy controls. Saliva 
composition was influenced by the higher concentration of urea in serum. So, our 
results suggest that salivary urea can be considered a marker for urea´s variation 
in serum. 
In literature it is described that increased salivary urea levels could induce to 
calculus formation and contributes to the remineralization of dental enamel. [2, 168] 
These two processes lead to a lower caries experience and were demonstrated in a 
study with children. [2, 168] In our study no differences concerning DMFT index were 
observed among the three groups. Similar results have been reported in literature. 
[169] 
Uric acid 
In the present study HD group had lower levels of salivary uric acid than RTRs or 
LKDs group. Interestingly, the salivary levels of uric acid in HD patients did not 
reflect the serum levels. 
Higher serum uric acid levels are associated with hypertension and diabetes 
mellitus, two major risk factors for CKD. In addition, this altered biochemical 
parameter has been shown to be associated with CVD. [170] Cardiovascular disease 
is the leading cause of morbidity and mortality in HD patients and RTRs.[4] 
STUDY OF ORAL HEALTH STATUS IN RENAL TRANSPLANT RECIPIENTS 
Discussion 
 
 
106 
Uric acid can be found in serum and saliva. In saliva, uric acid appears to be the 
dominant antioxidant and it is also an important biomarker with clinical 
importance in monitoring the oxidative stress. [171, 172] 
Antioxidants represent one of the defense mechanisms against oxidative stress 
which are present in all body fluids and tissues, including saliva. [172] The decrease 
in the levels of these important salivary antioxidants can be considered an 
important mechanism by which toxic effects of free radicals can initiate oral 
diseases and destroy the oral cavity homeostasis. [172] So, one can hypothesize that 
patients undergoing HD are less protected to oxidative damage than both RTRs 
and LKDs. 
Oxidative stress is implicated now in the pathology of several oral diseases, such as 
periodontitis. [172, 173] In periodontitis, polymorphonuclear leukocytes (PMN) 
produce a range of antimicrobial factors, such as reactive oxygen species during 
phagocytosis, this culminates in an increased oxidative damage to gingival tissue, 
periodontal ligament and alveolar bone. [172, 174] So, one can hypothesize that 
patients undergoing HD are less protected to oxidative damage that leads to 
periodontal disease. 
In our results HD patients had lower levels of uric acid in saliva and higher levels of 
uric acid in serum when compared with RTRs and LKDs groups. These were 
unexpected results considering what has been reported in literature. Further 
studies are necessary to clarify this finding. 
Creatinine 
In the present study HD patients had higher levels of salivary creatinine than RTRs 
and LKDs groups. Interestingly, the salivary levels of creatinine in HD patients 
reflect the serum levels when compared with healthy controls. 
Creatinine is a product of muscle metabolism and is excreted by kidneys. [166] The 
renal excretion of creatinine is independent of the rate of urine flow except for the 
cases in which the flow is much less than 0.5 ml. per minute. [166] 
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In literature the importance of creatinine assessment in saliva, for predicting 
serum levels, is considered limited.  [175] Its value in the qualitative monitoring of 
renal function may, however, be useful. [175] 
In our results, salivary creatinine levels in HD patients have reflected serum levels 
when compared with healthy controls. So, saliva composition in this group was 
influenced by the higher creatinine serum levels. 
However when comparing creatinine´s ratio between RTRs and healthy controls 
differences were found. So, in this group salivary creatinine was not an useful 
marker for serum levels when compared with healthy controls. 
 
3.3 Lipid profile 
Low-density lipoproteins, triglycerides 
In our study HD group had higher levels of salivary LDL than RTRs group, and 
saliva LDL levels in HD group reflected the serum levels when comparing with 
healthy controls.  Concerning salivary triglycerides, HD patients had higher levels 
than RTRs and LKDs groups.  In addition, in HD patients triglycerides salivary 
levels reflected serum levels when compared with healthy controls. 
A patient´s lipid profile (total cholesterol, LDL, HDL and triglycerides) is used in 
diagnosis and treatment of hyper- or dyslipidemia.[4] Chronic kidney disease 
population is prone to suffer from complex forms of dyslipidemia as well as 
significant CVD.[4] 
Dyslipidemia in HD patients is more frequent than in the general population and is 
characterized by hypertriglyceridemia and low levels of HDL. [4] However, levels of 
total cholesterol and LDL are usually normal. [4] 
The prevalence of lipid changes in RTRs is very high. Increases in cholesterol and 
LDL are particularly common. [4] HDL is usually normal, and triglycerides are often 
increased. [4] 
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In our results the serum lipid profile in HD patients and RTRs followed the 
prevalence previous described. In fact, LDL serum levels were higher in RTRs than 
HD patients and LKDs, and triglycerides serum levels were higher in HD patients 
than RTRs and LKDs groups. 
In our study when we compared RTRs and HD patients with healthy controls, we 
found that salivary lipid profile reflected serum lipid profile. So, we can 
hypothesize that salivary lipid profile can be considered a marker for lipid profile 
variation in serum for HD patients and RTRs. 
However, differences in lipid profile ratios were found when we compared RTRs 
with HD patients. 
 
3.4 Proteins 
C-reactive protein 
In the present study RTRs receiving Tac presented higher CRP salivary levels than 
RTRs receiving CsA and ERL. 
For RTRs receiving ERL our results have shown an inverse variation between 
salivary and serum CRP levels, when compared with RTRs receiving CsA and Tac. 
In addition, in RTRs receiving CsA and Tac salivary CRP levels have reflected serum 
levels. 
C-reactive protein is an acute phase protein synthesized by the liver hepatocytes in 
response to pro-inflammatory cytokines, and it is found in the blood. [176, 177]  
Acute-phase proteins are defined as proteins whose serum concentration is altered 
by at least 25% in response to inflammation. [176, 177] Synthesis of the acute phase 
protein CRP increases dramatically in response to infection, but mildly elevated 
levels are also associated with chronic inflammation. [178] In addition, other 
potential stimuli including smoking, obesity and trauma, may also account for mild 
increases in CRP. [179, 180] 
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Our results show that RTRs receiving ERL had higher serum CRP levels than RTRs 
receiving CsA and RTRs receiving Tac. Given that CRP is a non-specific marker of 
the acute-phase response and is considered one of the most sensitive markers to 
assess an individual inflammatory status, our results suggest that RTRs receiving 
ERL had an ongoing or chronic inflammation. 
Unrecognized infections, such as periodontitis, are commonly associated with an 
enhanced inflammatory response and may induce an acute-phase response, 
elevating CRP levels. [181] Recent studies of healthy populations have shown that 
periodontal infections are associated with elevated serum CRP values. [123, 147, 182, 
183] 
From another perspective, serum CRP in literature is not described as being 
specifically increased due to periodontal disease, but is increased due to 
inflammatory conditions caused by many other systemic diseases. [123] Besides 
that, if serum CRP is used for screening of periodontal disease there is the risk of a 
crossover effect against a background of systemic diseases. [123] Thus, there are no 
blood parameters known that exhibit high levels specifically as a result of 
periodontal disease. [123] 
Although CRP is primarily synthesized in the liver, some studies show that human 
gingiva is able to produce CRP in situ. [181, 184, 185] Because of its non-lipophilic 
structure and high molecular weight CRP is likely to show limited transfer from 
blood to saliva. [177, 186] 
Our results show that in RTRs receiving ERL serum CRP is not related with its 
salivary levels. Accordingly, the lack of association between serum and salivary 
CRP is described by Gomes-Filho. [187] 
In addition, our results have shown that RTRs receiving Tac had higher CRP levels 
in saliva than RTRs receiving CsA and RTRs receiving ERL. So, salivary CRP levels 
could have reflected a higher inflammatory activity in oral tissues in RTRs 
receiving Tac. Considering this, we have studied the correlation between salivary 
CRP levels and inflammatory signs in oral cavity, namely BOP scores. In our results, 
a positive correlation between salivary CRP levels and BOP was only found for 
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RTRs receiving Tac (data not shown), this was an unexpected finding considering 
that both CsA and Tac are pro-inflammatory and for both groups high BOP scores 
were found. Further studies are necessary to clarify this finding. 
 
Aspartate aminotransferase 
In the present study HD patients presented higher salivary AST levels than RTRs 
and LKDs. Interestingly, the salivary levels of AST in HD patients and RTRs 
reflected AST serum levels when compared with healthy controls. Given that 
salivary AST is released from injured and dead cells, these findings suggest that HD 
patients had more tissue damage in oral cavity than RTRs or LKDs groups. 
The enzyme AST is a useful marker following tissue damage. The AST is released 
from injured and dead cells into extracellular fluid and can be readily assayed in 
serum, tears and in oral cavity (gingival crevicular fluid and saliva). [188]. In saliva, 
higher levels of AST indicate increased cell damage in soft tissues, such as 
periodontium, and metabolic changes in the inflamed gingival tissues. [123, 188] 
Accordingly to Nomura and co-workers [123] salivary AST may be a candidate for 
the screening of periodontitis. In addition, some studies reported a correlation 
between AST levels in saliva and the progression of periodontal disease. [188-190] 
In our results salivary AST levels reflected serum levels in RTRs and HD patients 
when compared with healthy controls. However, this was not found between RTRs 
and HD patients. 
When we compared RTRs receiving CsA, Tac and ERL, lower levels of salivary AST 
were found in RTRs receiving Tac. 
Lactate dehydrogenase 
In the present study RTRs had lower salivary LDH levels than both HD and LKDs 
groups. The enzyme LDH is a ubiquitous enzyme that plays a significant role in the 
clinical diagnosis of pathological processes. [123] 
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The origin of LDH in saliva is being attributed to an extra-salivary gland source and 
serum, or bacteria. [123] In literature, salivary LDH has been investigated has a 
biochemical marker candidate for the screening of periodontal disease. [123] 
Currently, low and normal levels of LDH do not usually indicate a problem. 
 
Alkaline phosphatase 
In the present study HD patients had higher levels of salivary ALP than RTRs 
group. Interestingly, the salivary levels of ALP in HD patients and RTRs reflect the 
serum levels when compared with healthy controls. 
The enzyme ALP is produced by many cells, such as PMN, osteoblasts, 
macrophages, and fibroblasts within the area of the periodontium and gingival 
crevice. [191] Its main role is in the normal turnover of periodontal ligament, root 
cementum and maintenance, and bone homeostasis. [192, 193] ALP was one of the 
first host enzymes proposed as diagnostic indicators of periodontal status. [194] 
Given that ALP is released from PMN during inflammation [195] and from 
osteoblasts [196] and periodontal ligament fibroblasts [197] during bone formation 
and periodontal regeneration, respectively [193], our results show that HD patients 
had higher turnover in these tissues than RTRs. 
 
3.5 Immunoglobulins 
Immuglobulin A and Immunoglobulin G 
In our study RTRs presented lower IgA levels when compared with HD group. 
Interestingly, the salivary levels of IgA in HD patients and RTRs reflect the serum 
levels when compared with healthy controls. Given that immunological protection 
of mucosal surfaces is mediated primarily by the secretory immune system, 
particularly IgA in secretions, RTRs were less protected to the adherence and 
penetration of microorganisms and foreign proteins to oral tissues. 
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Immunoglobulin A is the second most common serum immunoglobulin and it is 
produced by plasma cells. Immunoglobulin A is the predominant immunoglobulin 
secreted in oral mucosal sites and is considered to be a major factor contributing 
to mucosal health and microbial defense. [198] As IgA passes into the secretions, the 
epithelial cells produce a protein that is added to it, known as secretory piece. The 
secretory piece helps IgA to be transported across mucosa and also protects it 
from degradation in the secretions. 
Secretory IgA has a wide range of biological activities against pathogens and is 
believed to act as an immune barrier to prevent adherence and absorption of 
microbes and various other antigens to the mucosa. Furthermore, it can neutralize 
intracellular microbial pathogens within the epithelial cells and facilitate their 
exclusion into the lumen. [198] Additionally, secretory IgA may play a key role in 
protection against oral candidiasis.[199] 
Serum IgG is responsible for all the immunoglobulin molecules functions.  Salivary 
IgG is an ultrafiltrate of serum IgG, which is modified by the host’s general immune 
response.[200] 
In kidney transplantation immunosuppressive therapy is used to inhibit or prevent 
activity of the immune system against allograft. However, in RTRs 
immunosuppressive therapy increases the incidence of infection and 
malignancy.[55] 
In our study RTRs presented lower salivary IgA and IgG levels when compared 
with HD group. So, RTRs are more prompt to infection in oral tissues than HD 
patients. Furthermore, salivary levels of IgA in RTRs and HD patients reflected IgA 
serum levels when compared with healthy controls. 
In literature, the protective role of salivary IgA against dental diseases has been a 
controversial matter [198]. In our study, even though RTRs had lower salivary IgA 
than HD patients, no differences were found in dental disease among the studied 
groups. Similar results were found in literature [198] and this could be explained 
using two perspectives; one is the capacity of immune system to compensate the 
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decreased of IgA, the other is the minor protective role of salivary IgA against 
dental disease. 
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Chapter V – Conclusion 
 
 
 
The following conclusions can be drawn from the present study: 
− Renal transplant recipients receiving ERL have lower periodontal 
inflammation and may be better protected for the development of 
periodontal disease when compared to RTRs receiving calcineurin 
inhibitors (CsA and Tac). 
− The RTRs medicated with Tac differ from those medicated with CsA and 
ERL in the composition of saliva, namely: potassium, phosphate, C-reactive 
protein and aspartate aminotransferase.  
− Patients on hemodialysis have lower rates of salivary secretion compared 
with renal transplant recipients. 
− Patients on hemodialysis differ from RTRs in the composition of saliva, 
namely: potassium, urea, creatinine, uric acid, cholesterol-LDL, 
triglycerides, aspartate aminotransferase, lactate dehydrogenase, alkaline 
phosphatase, and immunoglobulin A.  
− Renal transplant recipients receiving Tac had higher salivary CRP levels this 
could be considered an indicator of a higher inflammatory activity in oral 
tissues. 
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